≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Defects in the complement system

DOID Endpoint Browser PheWeb

D3_COMPLEMENTDEF

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D84.1
  • Hospital discharge: ICD-9 — 2798B
  • Cause of death: ICD-10 — D84.1
  • Cause of death: ICD-9 — 2798B

2 out of 7 registries used, show all original rules.

264

4. Check minimum number of events

None

264

5. Include endpoints

None

264

6. Filter based on genotype QC (FinnGen only)

250

Control definitions (FinnGen only)

Control exclude
D3_IMMUNEMECHANISM

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D84
Name in latin
Deficientia systematis complementi

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1516 980 531
Only index persons 1328 892 436
Unadjusted period prevalence (%)
Whole population 0.02 0.03 0.01
Only index persons 0.03 0.03 0.02
Median age at first event (years)
Whole population 36.99 41.26 28.98
Only index persons 40.75 42.47 37.23

-FinnGen-

Key figures

All Female Male
Number of individuals 250 189 61
Unadjusted period prevalence (%) 0.06 0.07 0.03
Median age at first event (years) 45.41 45.39 45.45

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
264
Matched controls
2640
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D84.18
ICD-10 Finland
Other specified defect in the complement system
+∞
136.7
119
*
T78.3
ICD-10 Finland
Angioneurotic oedema
68.7
119.9
67
13
D84.1
ICD-10 Finland
Defects in the complement system
+∞
82.8
75
*
D84.19
ICD-10 Finland
Unspecified defect in the complement system
+∞
73.4
67
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
13.2
54.3
57
54
H02AB06
ATC
prednisolone; systemic
7.1
46.8
203
840
D84.11
ICD-10 Finland
Hereditary angioedema type I
+∞
40.7
38
*
338
Kela drug reimbursment
C1-esterase inhibitor, icatibant and conestat alfa
+∞
39.6
37
*
D84.13
ICD-10 Finland
Hereditary angioedema type III
+∞
39.6
37
*
R03DC03
ATC
montelukast; oral
5.4
38.0
108
302
C01CA24
ATC
epinephrine; parenteral
6.8
36.4
68
129
B06AC02
ATC
icatibant; parenteral
+∞
36.3
34
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.7
34.4
129
445
ZX120
NOMESCO Finland
Intravenous
6.4
33.9
67
134
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.5
31.2
175
798
R60.9
ICD-10 Finland
Oedema, unspecified
8.9
31.1
42
55
D80.3
ICD-10 Finland
Selective deficiency of immunoglobulin G [IgG] subclasses
+∞
30.8
29
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.0
29.9
82
218
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
10.9
29.2
33
34
B02AA02
ATC
tranexamic acid; systemic
4.5
28.6
95
293
H02AB07
ATC
prednisone; oral
5.2
27.4
68
165
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
+∞
26.5
25
*
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
+∞
25.4
24
*
120
Kela drug reimbursment
Hypogammaglobulinaemia
+∞
25.4
24
*
H02AB09
ATC
hydrocortisone; systemic
8.8
24.8
33
42
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.3
24.3
34
46
TDM10
NOMESCO Finland
Puncture of maxillary antrum
8.0
23.5
34
48
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
5.4
23.1
52
115
H02AB04
ATC
methylprednisolone; systemic
4.5
23.1
70
198
XQ800
NOMESCO Finland
Prick test
5.0
22.7
56
134
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
+∞
22.2
21
*
R03BB04
ATC
tiotropium bromide; inhalant
5.9
21.8
43
84
J45.9
ICD-10 Finland
Asthma, unspecified
3.7
21.5
93
337
X59
ICD-10 Finland
Exposure to unspecified factor
3.7
20.8
91
332
WW200
NOMESCO Finland
Immunization
18.0
20.7
32
20
UJF32
NOMESCO Finland
Coloscopy
3.6
20.4
96
366
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
3.6
20.1
91
338
R50.9
ICD-10 Finland
Fever, unspecified
3.8
20.1
80
273
T78.4
ICD-10 Finland
Allergy, unspecified
6.1
19.6
37
69
R60.0
ICD-10 Finland
Localized oedema
4.5
19.6
56
150
J01MA14
ATC
moxifloxacin; systemic
5.0
19.4
47
110
J45.0
ICD-10 Finland
Predominantly allergic asthma
4.3
18.4
56
157
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.3
18.2
40
86
R06.0
ICD-10 Finland
Dyspnoea
3.2
18.1
101
423
B06AC05
ATC
lanadelumab; parenteral
+∞
17.9
17
*
D84.12
ICD-10 Finland
Hereditary angioedema type II
+∞
17.9
17
*
P01BA02
ATC
hydroxychloroquine; oral
4.8
17.7
44
105
TPH04
NOMESCO Finland
Cathetrisation of vein
3.3
17.6
90
357
UGC12
NOMESCO Finland
Flexible bronchoscopy
6.0
17.6
33
61
J01MA12
ATC
levofloxacin; systemic
3.7
17.3
68
228
R06AE07
ATC
cetirizine; oral
3.0
17.1
163
917
D80.8
ICD-10 Finland
Other immunodeficiencies with predominantly antibody defects
+∞
16.8
16
*
Z01.8
ICD-10 Finland
Other specified special examinations
3.2
16.8
92
379
J45.8
ICD-10 Finland
Mixed asthma
7.9
16.8
24
33
R06AE09
ATC
levocetirizine; oral
3.4
16.4
73
265
J01FF01
ATC
clindamycin; systemic
3.0
16.0
98
429
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.0
15.9
51
148
J01MA02
ATC
ciprofloxacin; systemic
2.9
15.7
118
577
C08DA01
ATC
verapamil; systemic
7.0
15.7
25
39
WZC30
NOMESCO Finland
Teaching
3.3
15.5
73
273
R03AK06
ATC
salmeterol and fluticasone; inhalant
3.5
15.4
63
216
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.8
15.2
139
749
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.1
15.1
82
334
J31.0
ICD-10 Finland
Chronic rhinitis
4.0
15.0
49
144
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
5.9
14.8
28
52
D84.9
ICD-10 Finland
Immunodeficiency, unspecified
+∞
14.7
14
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
4.4
14.4
40
104
A02BC01
ATC
omeprazole; systemic
2.9
14.2
92
412
J45.1
ICD-10 Finland
Nonallergic asthma
4.0
14.1
44
125
ZYC01
NOMESCO Finland
Remote contact by phone
4.1
13.8
41
112
C03CA01
ATC
furosemide; systemic
3.1
13.8
73
291
UJF92
NOMESCO Finland
Capsular endoscopy
12.4
13.6
24
21
UJF30
NOMESCO Finland
Ileoscopy through colon
3.9
13.6
45
133
J47
ICD-10 Finland
Bronchiectasis
22.6
13.5
19
9
B34.9
ICD-10 Finland
Viral infection, unspecified
5.9
13.3
25
46
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
11.9
13.3
24
22
R06AX27
ATC
desloratadine; oral
2.6
13.1
122
651
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
4.5
12.7
33
81
B06AC01
ATC
c1-inhibitor, plasma derived; parenteral
+∞
12.6
12
*
R03AC02
ATC
salbutamol; inhalant
2.8
12.6
190
1272
N03AX16
ATC
[U] pregabalin
2.8
12.6
79
345
N06AX21
ATC
duloxetine; oral
3.2
12.4
57
208
R03AK08
ATC
formoterol and beclometasone; inhalant
5.1
12.2
27
58
SPAT1255
SPAT
Intravenous administration of medicine
5.2
12.2
26
54
Z31.5
ICD-10 Finland
Genetic counselling
3.7
11.8
42
130
A06AD11
ATC
lactulose; oral
3.6
11.6
43
137
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.6
11.5
41
127
A01AB09
ATC
miconazole; local oral
4.0
11.5
35
97
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.7
11.5
77
346
J01FA06
ATC
roxithromycin; oral
2.5
11.5
124
700
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.8
11.5
69
293
R01AD08
ATC
fluticasone; nasal
2.5
11.3
108
576
J45
ICD-10 Finland
Asthma
3.3
11.2
47
162
E0000UV, ,
ATC
2.4
11.2
139
833
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
10.8
99
515
EP1AE
NOMESCO Finland
Neck ultrasound examination
4.3
10.8
29
73
N02AX02
ATC
tramadol; systemic, rectal
2.4
10.8
122
698
G47.3
ICD-10 Finland
Sleep apnoea
2.6
10.7
76
350
M79.7
ICD-10 Finland
Fibromyalgia
5.0
10.7
24
52
WX408
NOMESCO Finland
General anesthesy, balanced
2.5
10.6
92
466
R01AD05
ATC
budesonide; nasal
3.8
10.6
34
98
R03BA08
ATC
ciclesonide; inhalant
3.4
10.5
41
135
K52.9
ICD-10 Finland
Noninfective gastroenteritis and colitis, unspecified
5.0
10.5
23
49
R03AK07
ATC
formoterol and budesonide; inhalant
2.6
10.4
79
376
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
3.2
10.2
46
165
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
4.2
10.1
28
72
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.4
10.0
176
1204
R03AC12
ATC
salmeterol; inhalant
4.9
9.7
22
48
M79.0
ICD-10 Finland
Rheumatism, unspecified
5.1
9.7
21
44
A02BC02
ATC
pantoprazole; systemic
2.4
9.7
183
1283
ZXA10
NOMESCO Finland
Bilateral
2.6
9.6
65
291
N05BA01
ATC
diazepam; systemic, rectal
3.0
9.5
47
178
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.5
9.5
73
348
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.3
9.5
96
518
R03DA04
ATC
theophylline; systemic, rectal
7.8
9.4
21
29
L01BA01
ATC
methotrexate; systemic
8.2
9.3
20
26
L04AX01
ATC
azathioprine; systemic
4.7
9.3
22
50
R51.80
ICD-10 Finland
Headache
2.5
9.3
72
344
R75
ICPC
Sinusitis acute/chronic
4.0
9.1
27
73
ZXE10
NOMESCO Finland
More than one and less than three hours
2.2
9.1
110
637
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
38.1
9.1
11
*
6BA02, ,
NOMESCO Finland
38.1
9.1
11
*
L50.9
ICD-10 Finland
Urticaria, unspecified
4.1
9.0
26
69
R04
ICPC
Breathing problem other
4.8
9.0
21
47
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
5.0
9.0
20
43
R01AD58
ATC
fluticasone, combinations; nasal
2.3
8.9
92
498
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.5
8.8
32
100
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.2
8.7
37
128
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.0
8.6
43
163
R53
ICD-10 Finland
Malaise and fatigue
2.3
8.6
85
450
R01AD09
ATC
mometasone; nasal
2.2
8.6
150
999
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.4
8.6
32
102
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
8.3
8.5
18
23
J32.4
ICD-10 Finland
Chronic pansinusitis
13.4
8.5
14
11
XF400
NOMESCO Finland
ECG with 12 standard connections
2.7
8.5
50
208
A07AA02
ATC
nystatin; oral
4.0
8.4
25
68
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
3.8
8.4
26
73
A06AC01
ATC
ispaghula (psylla seeds); oral
2.3
8.3
78
404
R03BA02
ATC
budesonide; inhalant
2.4
8.3
71
353
R03BA05
ATC
fluticasone; inhalant
2.3
8.2
75
383
C03DA01
ATC
spironolactone; oral
3.1
8.2
36
127
ZY010
NOMESCO Finland
Hospital outpatient
3.3
8.2
32
105
N03AX12
ATC
[U] gabapentin; oral
2.6
8.1
55
245
L04AB04
ATC
adalimumab; parenteral
7.6
8.1
18
25
K58.0
ICD-10 Finland
Irritable bowel syndrome with diarrhoea
3.4
8.1
30
95
C08CA13
ATC
lercanidipine; oral
2.9
8.1
42
163
Z3226
NOMESCO Finland
Physiotherapist
2.4
8.1
67
328
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.6
8.0
27
80
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.0
8.0
37
134
M54.4
ICD-10 Finland
Lumbago with sciatica
2.4
8.0
67
329
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
4.9
8.0
18
39
Z3231
NOMESCO Finland
Registered nurse
2.2
8.0
97
557
T78.2
ICD-10 Finland
Anaphylactic shock, unspecified
13.6
8.0
13
10
R01BA51
ATC
phenylpropanolamine, combinations; oral
2.8
7.9
43
171
L04AX03
ATC
methotrexate; systemic
3.0
7.9
36
130
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.7
7.8
48
203
J05AB11
ATC
valaciclovir; oral
2.5
7.8
58
270
4AA12, ,
NOMESCO Finland
46.4
7.8
9
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.9
7.7
38
143
J01FA10
ATC
azithromycin; systemic
2.2
7.7
185
1368
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
19.0
7.7
11
6
X57
ICD-10 Finland
Unspecified privation
7.5
7.6
17
24
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
3.0
7.6
35
127
JN3AD
NOMESCO Finland
Abdominal CT examination
2.7
7.6
43
175
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
4.6
7.6
18
41
N02AA05
ATC
oxycodone; systemic
2.6
7.5
47
201
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.8
7.4
39
152
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
7.2
7.4
17
25
R06AX26
ATC
fexofenadine; oral
3.1
7.4
32
112
D80.2
ICD-10 Finland
Selective deficiency of immunoglobulin A [IgA]
+∞
7.3
7
*
2776B
ICD-9 Finland
Other and unspecified disorders of metabolism, Other deficiencies of circulating enzymes[OEDEMA ANGIONEUROTICUM HEREDITARIUM (HANE)]
+∞
7.3
7
*
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.2
7.3
85
477
ZXD31
NOMESCO Finland
Major difficulties in performing procedure
4.2
7.3
20
51
SPAT1229
SPAT
Assessment of need for aid
4.0
7.2
21
56
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
3.6
7.2
24
71
Z2446
NOMESCO Finland
Social worker
2.9
7.2
36
137
N03AE01
ATC
clonazepam; systemic
3.9
7.1
21
57
ZYC05
NOMESCO Finland
Non-real-time text-based remote communication
7.9
7.0
15
20
L50.8
ICD-10 Finland
Other urticaria
7.0
6.9
16
24
ZXD10
NOMESCO Finland
Scheduled procedure
2.0
6.9
110
692
UDQ12
NOMESCO Finland
Flexible laryngoscopy
3.4
6.9
25
78
D07AB02
ATC
hydrocortisone butyrate; topical
2.1
6.9
90
527
ZY010, ,
SPAT
11.4
6.9
12
11
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.2
6.9
65
335
XG410
NOMESCO Finland
Flow-volume spirometry
4.5
6.9
17
40
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.0
6.9
31
111
FP1B5
NOMESCO Finland
Resting ECG, 12 leads
7.5
6.8
15
21
WX892
NOMESCO Finland
Monitored bed care
3.3
6.8
26
84
R42
ICD-10 Finland
Dizziness and giddiness
2.2
6.8
64
329
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
17.2
6.8
10
6
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
41.1
6.8
8
*
W84
ICD-10 Finland
Unspecified threat to breathing
41.1
6.8
8
*
WZC00
NOMESCO Finland
Treatment plan or consultation
2.0
6.8
115
738
S01GX01
ATC
cromoglicic acid; ophthalmic
2.1
6.8
75
412
R4120
NOMESCO Finland
Occupational therapy
3.0
6.7
31
112
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
3.0
6.7
31
112
M35.7
ICD-10 Finland
Hypermobility syndrome
8.1
6.7
14
18
M54.9
ICD-10 Finland
Dorsalgia, unspecified
2.5
6.7
47
212
N06AA09
ATC
amitriptyline; systemic
3.0
6.6
31
113
L04AB01
ATC
etanercept; parenteral
12.7
6.6
11
9
J32.9
ICD-10 Finland
Chronic sinusitis, unspecified
9.0
6.6
13
15
M25.5
ICD-10 Finland
Pain in joint
2.0
6.6
107
674
A02BC05
ATC
esomeprazole; systemic
2.0
6.6
109
692
A03FA02
ATC
cisapride; oral, rectal
3.5
6.6
23
70
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.7
6.6
39
162
WVA20, ,
SPAT
4.1
6.6
18
46
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.2
6.5
64
334
R01AD12
ATC
fluticasone furoate; nasal
2.0
6.5
107
677
M54.3
ICD-10 Finland
Sciatica
3.5
6.4
22
66
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
6.2
6.4
16
27
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
3.1
6.4
27
93
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
2.7
6.4
37
152
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
2.9
6.3
31
116
R07.0
ICD-10 Finland
Pain in throat
2.8
6.3
32
122
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
2.6
6.3
38
159
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
3.5
6.3
22
67
D84.8
ICD-10 Finland
Other specified immunodeficiencies
+∞
6.3
6
*
D80.0
ICD-10 Finland
Hereditary hypogammaglobulinaemia
+∞
6.3
6
*
D84.14
ICD-10 Finland
C1 esterase inhibitor deficiency (C1-INH deficiency)
+∞
6.3
6
*
A02BC03
ATC
lansoprazole; oral
2.1
6.2
76
432
WX722
NOMESCO Finland
PEEP
4.0
6.2
18
48
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.4
6.2
23
73
R06.5
ICD-10 Finland
Mouth breathing
2.8
6.1
33
130
TLC00
NOMESCO Finland
Insertion of intrauterine device
2.8
6.1
32
124
A08
ICPC
Swelling
3.6
6.1
20
58
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
6.1
113
740
J01DA08
ATC
[U] cefaclor
2.6
6.1
37
155
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
7.0
6.1
14
21
ZXH09, ,
SPAT
5.8
6.1
16
29
H02BX01
ATC
methylprednisolone, combinations; systemic
5.8
6.1
16
29
Z2221
NOMESCO Finland
Medical doctor
2.0
6.0
88
532

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Pharmacy visit
OMOP4822462 [581458]
1.1e+00
1.8e+00
1.2e+00
1.9e+00
1.6e+00
1.8e+00
1.0e+50
cases:98.05%
controls:94.32%
cases:96.89%
controls:83.23%
cases:67.70%
controls:39.35%
cases:15.56%
controls:2.65%
cases:75.10%
controls:38.95%
cases:96.44%
controls:82.27%
cases:100.00%
controls:95.31%
251
2409
5
145
249
2134
8
430
174
1009
83
1555
40
68
217
2496
193
997
64
1563
244
2084
9
449
235
2237
0
110
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.5e+00
2.6e+00
3.2e+00
1.0e+50
3.0e+00
2.9e+00
2.4e+00
cases:23.05%
controls:6.19%
cases:26.46%
controls:2.54%
cases:8.17%
controls:0.35%
cases:18.68%
controls:0.00%
cases:10.51%
controls:0.59%
cases:31.23%
controls:2.49%
cases:42.55%
controls:6.48%
59
158
197
2396
68
65
189
2499
21
9
236
2555
48
0
209
2564
27
15
230
2545
79
63
174
2470
100
152
135
2195
Outpatient Visit
OP [9202]
1.1e+00
1.7e+00
1.5e+00
5.9e+00
1.9e+00
2.1e+00
1.4e+00
cases:87.11%
controls:68.79%
cases:82.49%
controls:47.35%
cases:37.74%
controls:11.43%
cases:62.26%
controls:0.47%
cases:45.14%
controls:11.05%
cases:86.96%
controls:45.16%
cases:93.62%
controls:78.23%
223
1757
33
797
212
1214
45
1350
97
293
160
2271
160
12
97
2552
116
283
141
2277
220
1144
33
1389
220
1836
15
511
prednisolone
A07EA01 [21600653]
2.2e+00
2.5e+00
2.5e+00
—
2.6e+00
2.1e+00
1.8e+00
cases:46.88%
controls:8.77%
cases:36.19%
controls:4.33%
cases:8.95%
controls:0.82%
—
—
cases:7.00%
controls:0.55%
cases:26.09%
controls:4.07%
cases:37.87%
controls:9.20%
120
224
136
2330
93
111
164
2453
23
21
234
2543
—
18
14
239
2546
66
103
187
2430
89
216
146
2131
prednisolone; oral, parenteral
H02AB06 [21602734]
2.2e+00
2.5e+00
2.5e+00
—
2.6e+00
2.1e+00
1.8e+00
cases:46.48%
controls:8.73%
cases:36.19%
controls:4.33%
cases:8.95%
controls:0.82%
—
—
cases:7.00%
controls:0.55%
cases:26.09%
controls:4.07%
cases:37.87%
controls:9.12%
119
223
137
2331
93
111
164
2453
23
21
234
2543
—
18
14
239
2546
66
103
187
2430
89
214
146
2133
Infectious Disease
44 [38004484]
2.6e+00
3.9e+00
—
—
—
4.4e+00
2.9e+00
cases:12.11%
controls:0.98%
cases:21.01%
controls:0.55%
—
—
—
—
—
—
cases:27.27%
controls:0.47%
cases:26.38%
controls:2.00%
31
25
225
2529
54
14
203
2550
—
—
—
69
12
184
2521
62
47
173
2300
montelukast; oral
R03DC03 [21603356]
2.0e+00
2.0e+00
2.6e+00
—
2.7e+00
2.2e+00
1.7e+00
cases:21.09%
controls:3.52%
cases:11.67%
controls:1.76%
cases:4.67%
controls:0.35%
—
—
cases:3.89%
controls:0.27%
cases:14.23%
controls:1.78%
cases:18.72%
controls:3.88%
54
90
202
2464
30
45
227
2519
12
9
245
2555
—
10
7
247
2553
36
45
217
2488
44
91
191
2256
Pulmonary Disease
29 [38004472]
1.5e+00
2.3e+00
2.8e+00
1.0e+50
2.5e+00
2.3e+00
1.9e+00
cases:21.88%
controls:5.83%
cases:21.79%
controls:2.81%
cases:6.23%
controls:0.39%
cases:3.89%
controls:0.00%
cases:6.23%
controls:0.55%
cases:20.55%
controls:2.61%
cases:29.79%
controls:6.09%
56
149
200
2405
56
72
201
2492
16
10
241
2554
10
0
247
2564
16
14
241
2546
52
66
201
2467
70
143
165
2204
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
1.6e+00
2.2e+00
3.1e+00
—
2.2e+00
2.2e+00
1.5e+00
cases:10.16%
controls:2.19%
cases:13.23%
controls:1.64%
cases:6.61%
controls:0.31%
—
—
cases:2.33%
controls:0.27%
cases:13.04%
controls:1.58%
cases:19.15%
controls:5.20%
26
56
230
2498
34
42
223
2522
17
8
240
2556
—
6
7
251
2553
33
40
220
2493
45
122
190
2225
Rheumatology
66 [38004491]
1.8e+00
1.8e+00
2.3e+00
—
1.8e+00
2.0e+00
2.1e+00
cases:15.23%
controls:2.86%
cases:8.17%
controls:1.48%
cases:3.11%
controls:0.31%
—
—
cases:3.11%
controls:0.51%
cases:11.86%
controls:1.82%
cases:18.72%
controls:2.77%
39
73
217
2481
21
38
236
2526
8
8
249
2556
—
8
13
249
2547
30
46
223
2487
44
65
191
2282
Internal Medicine
11 [38004456]
1.3e+00
2.0e+00
2.5e+00
—
2.4e+00
1.9e+00
1.5e+00
cases:42.19%
controls:16.44%
cases:34.24%
controls:6.59%
cases:11.67%
controls:1.09%
—
—
cases:13.23%
controls:1.37%
cases:30.83%
controls:6.47%
cases:42.98%
controls:14.32%
108
420
148
2134
88
169
169
2395
30
28
227
2536
—
34
35
223
2525
78
164
175
2369
101
336
134
2011
Medical doctor
Z2221 [2001311556]
1.0e+00
1.9e+00
2.3e+00
—
2.6e+00
1.9e+00
1.8e+00
cases:15.63%
controls:6.23%
cases:12.84%
controls:2.15%
cases:4.28%
controls:0.43%
—
—
cases:3.11%
controls:0.23%
cases:9.88%
controls:1.66%
cases:17.87%
controls:3.58%
40
159
216
2395
33
55
224
2509
11
11
246
2553
—
8
6
249
2554
25
42
228
2491
42
84
193
2263
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
1.8e+00
3.7e+00
1.0e+50
—
—
3.3e+00
2.6e+00
cases:5.47%
controls:0.94%
cases:15.95%
controls:0.47%
cases:6.23%
controls:0.00%
—
—
—
—
cases:9.09%
controls:0.36%
cases:19.15%
controls:1.75%
14
24
242
2530
41
12
216
2552
16
0
241
2564
—
—
23
9
230
2524
45
41
190
2306
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2.2e+00
3.9e+00
1.0e+50
—
—
3.0e+00
2.4e+00
cases:5.47%
controls:0.67%
cases:14.40%
controls:0.35%
cases:4.28%
controls:0.00%
—
—
—
—
cases:5.93%
controls:0.32%
cases:13.19%
controls:1.36%
14
17
242
2537
37
9
220
2555
11
0
246
2564
—
—
15
8
238
2525
31
32
204
2315
salmeterol and fluticasone
R03AK06 [21603280]
1.6e+00
2.1e+00
2.0e+00
—
1.8e+00
2.1e+00
1.7e+00
cases:12.89%
controls:2.82%
cases:12.84%
controls:1.76%
cases:4.28%
controls:0.59%
—
—
cases:4.28%
controls:0.74%
cases:12.65%
controls:1.82%
cases:13.19%
controls:2.73%
33
72
223
2482
33
45
224
2519
11
15
246
2549
—
11
19
246
2541
32
46
221
2487
31
64
204
2283
Asthma, unspecified
J45.9 [45562456]
2.0e+00
2.3e+00
2.3e+00
1.0e+50
2.5e+00
2.4e+00
2.1e+00
cases:14.06%
controls:2.15%
cases:9.34%
controls:0.98%
cases:1.95%
controls:0.20%
cases:3.89%
controls:0.00%
cases:3.11%
controls:0.27%
cases:9.49%
controls:0.99%
cases:17.02%
controls:2.39%
36
55
220
2499
24
25
233
2539
5
5
252
2559
10
0
247
2564
8
7
249
2553
24
25
229
2508
40
56
195
2291
Basophils [#/volume] in Blood
26444-0 [3006315]
1.2e+00
1.7e+00
2.7e+00
—
1.9e+00
1.8e+00
1.7e+00
cases:19.53%
controls:7.13%
cases:24.51%
controls:5.54%
cases:12.84%
controls:1.01%
—
—
cases:5.84%
controls:0.90%
cases:24.51%
controls:5.17%
cases:44.26%
controls:12.95%
50
182
206
2372
63
142
194
2422
33
26
224
2538
—
15
23
242
2537
62
131
191
2402
104
304
131
2043
Intravenous
ZX120 [2001311495]
2.3e+00
2.6e+00
—
—
—
3.1e+00
2.9e+00
cases:8.59%
controls:0.94%
cases:5.84%
controls:0.47%
—
—
—
—
—
—
cases:7.91%
controls:0.39%
cases:11.91%
controls:0.72%
22
24
234
2530
15
12
242
2552
—
—
—
20
10
233
2523
28
17
207
2330
Pediatric Gastroenterology
OMOP4822029 [45756810]
2.0e+00
2.7e+00
—
1.0e+50
—
3.1e+00
3.1e+00
cases:4.30%
controls:0.63%
cases:5.45%
controls:0.39%
—
—
cases:2.33%
controls:0.00%
—
—
cases:5.93%
controls:0.28%
cases:6.81%
controls:0.34%
11
16
245
2538
14
10
243
2554
—
6
0
251
2564
—
15
7
238
2526
16
8
219
2339
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.1e+00
1.7e+00
2.6e+00
—
2.0e+00
1.8e+00
1.7e+00
cases:19.14%
controls:7.13%
cases:23.74%
controls:5.54%
cases:12.45%
controls:1.01%
—
—
cases:5.84%
controls:0.86%
cases:24.11%
controls:5.17%
cases:43.83%
controls:12.91%
49
182
207
2372
61
142
196
2422
32
26
225
2538
—
15
22
242
2538
61
131
192
2402
103
303
132
2044
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
1.1e+00
1.7e+00
2.6e+00
—
1.8e+00
1.8e+00
1.7e+00
cases:19.53%
controls:7.44%
cases:24.51%
controls:5.69%
cases:12.84%
controls:1.13%
—
—
cases:5.84%
controls:0.98%
cases:24.90%
controls:5.41%
cases:45.11%
controls:13.42%
50
190
206
2364
63
146
194
2418
33
29
224
2535
—
15
25
242
2535
63
137
190
2396
106
315
129
2032
Eosinophils [#/volume] in Blood
26449-9 [3013115]
1.1e+00
1.6e+00
2.6e+00
—
1.9e+00
1.7e+00
1.6e+00
cases:20.70%
controls:7.83%
cases:24.12%
controls:5.93%
cases:12.84%
controls:1.13%
—
—
cases:5.84%
controls:0.94%
cases:24.51%
controls:5.37%
cases:44.26%
controls:13.68%
53
200
203
2354
62
152
195
2412
33
29
224
2535
—
15
24
242
2536
62
136
191
2397
104
321
131
2026
Otolaryngology
4 [38004449]
1.5e+00
1.6e+00
1.6e+00
—
2.5e+00
1.9e+00
1.3e+00
cases:32.81%
controls:10.18%
cases:16.34%
controls:3.71%
cases:3.50%
controls:0.70%
—
—
cases:5.06%
controls:0.43%
cases:19.37%
controls:3.47%
cases:26.38%
controls:8.73%
84
260
172
2294
42
95
215
2469
9
18
248
2546
—
13
11
244
2549
49
88
204
2445
62
205
173
2142
epinephrine
S01EA01 [21603673]
2.1e+00
2.9e+00
—
—
1.0e+50
2.7e+00
2.4e+00
cases:10.55%
controls:1.49%
cases:12.06%
controls:0.74%
—
—
—
—
cases:2.72%
controls:0.00%
cases:11.07%
controls:0.79%
cases:16.17%
controls:1.70%
27
38
229
2516
31
19
226
2545
—
—
7
0
250
2560
28
20
225
2513
38
40
197
2307
epinephrine; parenteral
C01CA24 [21600303]
2.1e+00
2.9e+00
—
—
1.0e+50
2.7e+00
2.4e+00
cases:10.55%
controls:1.49%
cases:12.06%
controls:0.74%
—
—
—
—
cases:2.72%
controls:0.00%
cases:11.07%
controls:0.79%
cases:16.17%
controls:1.70%
27
38
229
2516
31
19
226
2545
—
—
7
0
250
2560
28
20
225
2513
38
40
197
2307
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
1.9e+00
3.1e+00
—
—
—
2.8e+00
2.1e+00
cases:7.81%
controls:1.21%
cases:12.84%
controls:0.66%
—
—
—
—
—
—
cases:5.93%
controls:0.39%
cases:10.21%
controls:1.32%
20
31
236
2523
33
17
224
2547
—
—
—
15
10
238
2523
24
31
211
2316
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
8.6e-01
2.5e+00
3.3e+00
—
—
1.6e+00
1.4e+00
cases:8.20%
controls:3.64%
cases:15.95%
controls:1.48%
cases:5.06%
controls:0.20%
—
—
—
—
cases:6.72%
controls:1.42%
cases:19.57%
controls:5.75%
21
93
235
2461
41
38
216
2526
13
5
244
2559
—
—
17
36
236
2497
46
135
189
2212
tranexamic acid; oral, parenteral
B02AA02 [21601036]
1.6e+00
2.6e+00
—
1.0e+50
—
3.2e+00
2.3e+00
cases:10.94%
controls:2.51%
cases:11.67%
controls:1.01%
—
—
cases:4.28%
controls:0.00%
—
—
cases:16.60%
controls:0.79%
cases:17.87%
controls:2.09%
28
64
228
2490
30
26
227
2538
—
11
0
246
2564
—
42
20
211
2513
42
49
193
2298
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
9.9e-01
1.4e+00
2.4e+00
—
1.8e+00
1.5e+00
1.5e+00
cases:16.80%
controls:7.01%
cases:19.07%
controls:5.38%
cases:11.67%
controls:1.13%
—
—
cases:4.67%
controls:0.78%
cases:18.18%
controls:4.90%
cases:37.45%
controls:12.10%
43
179
213
2375
49
138
208
2426
30
29
227
2535
—
12
20
245
2540
46
124
207
2409
88
284
147
2063
Monocytes/Leukocytes in Blood
26485-3 [3019069]
9.7e-01
1.4e+00
2.4e+00
—
1.9e+00
1.5e+00
1.5e+00
cases:16.80%
controls:7.09%
cases:18.68%
controls:5.42%
cases:11.28%
controls:1.13%
—
—
cases:4.67%
controls:0.74%
cases:18.18%
controls:4.90%
cases:37.45%
controls:12.14%
43
181
213
2373
48
139
209
2425
29
29
228
2535
—
12
19
245
2541
46
124
207
2409
88
285
147
2062
Basophils/Leukocytes in Blood
30180-4 [3022096]
9.9e-01
1.4e+00
2.4e+00
—
1.8e+00
1.5e+00
1.5e+00
cases:16.80%
controls:7.01%
cases:18.29%
controls:5.38%
cases:11.67%
controls:1.13%
—
—
cases:4.67%
controls:0.78%
cases:18.18%
controls:4.90%
cases:37.45%
controls:12.06%
43
179
213
2375
47
138
210
2426
30
29
227
2535
—
12
20
245
2540
46
124
207
2409
88
283
147
2064
Localized oedema
R60.0 [45597193]
1.7e+00
3.1e+00
1.0e+50
—
—
2.5e+00
2.2e+00
cases:5.47%
controls:1.02%
cases:5.06%
controls:0.23%
cases:1.95%
controls:0.00%
—
—
—
—
cases:4.74%
controls:0.39%
cases:7.66%
controls:0.94%
14
26
242
2528
13
6
244
2558
5
0
252
2564
—
—
12
10
241
2523
18
22
217
2325
FEV1 --post bronchodilation
20155-8 [3023550]
1.6e+00
2.1e+00
—
—
—
3.0e+00
2.8e+00
cases:6.25%
controls:1.33%
cases:4.28%
controls:0.55%
—
—
—
—
—
—
cases:7.11%
controls:0.39%
cases:13.19%
controls:0.89%
16
34
240
2520
11
14
246
2550
—
—
—
18
10
235
2523
31
21
204
2326
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.6e+00
2.1e+00
—
—
—
3.0e+00
2.8e+00
cases:6.25%
controls:1.33%
cases:4.28%
controls:0.55%
—
—
—
—
—
—
cases:7.11%
controls:0.39%
cases:13.19%
controls:0.89%
16
34
240
2520
11
14
246
2550
—
—
—
18
10
235
2523
31
21
204
2326
FEV1 percent change
69983-5 [42868472]
1.6e+00
2.1e+00
—
—
—
3.0e+00
2.8e+00
cases:6.25%
controls:1.33%
cases:4.28%
controls:0.55%
—
—
—
—
—
—
cases:7.11%
controls:0.39%
cases:13.19%
controls:0.89%
16
34
240
2520
11
14
246
2550
—
—
—
18
10
235
2523
31
21
204
2326
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.6e+00
2.1e+00
—
—
—
3.0e+00
2.8e+00
cases:6.25%
controls:1.33%
cases:4.28%
controls:0.55%
—
—
—
—
—
—
cases:7.11%
controls:0.39%
cases:13.19%
controls:0.89%
16
34
240
2520
11
14
246
2550
—
—
—
18
10
235
2523
31
21
204
2326
FVC percent change Respiratory system
69982-7 [42868471]
1.6e+00
2.1e+00
—
—
—
3.0e+00
2.8e+00
cases:6.25%
controls:1.33%
cases:4.28%
controls:0.55%
—
—
—
—
—
—
cases:7.11%
controls:0.39%
cases:13.19%
controls:0.89%
16
34
240
2520
11
14
246
2550
—
—
—
18
10
235
2523
31
21
204
2326
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
9.3e-01
1.4e+00
2.4e+00
—
1.9e+00
1.4e+00
1.4e+00
cases:16.41%
controls:7.20%
cases:19.07%
controls:5.58%
cases:11.28%
controls:1.13%
—
—
cases:5.06%
controls:0.82%
cases:18.58%
controls:5.17%
cases:37.45%
controls:12.65%
42
184
214
2370
49
143
208
2421
29
29
228
2535
—
13
21
244
2539
47
131
206
2402
88
297
147
2050
Predominantly allergic asthma
J45.0 [45557624]
2.3e+00
2.3e+00
—
1.0e+50
—
2.8e+00
2.0e+00
cases:12.11%
controls:1.37%
cases:7.00%
controls:0.78%
—
—
cases:3.89%
controls:0.00%
—
—
cases:8.70%
controls:0.59%
cases:10.21%
controls:1.45%
31
35
225
2519
18
20
239
2544
—
10
0
247
2564
—
22
15
231
2518
24
34
211
2313
tiotropium bromide; inhalant
R03BB04 [21603296]
1.7e+00
1.7e+00
2.2e+00
—
—
1.8e+00
2.0e+00
cases:5.47%
controls:1.10%
cases:4.67%
controls:0.90%
cases:2.72%
controls:0.31%
—
—
—
—
cases:5.53%
controls:0.95%
cases:9.79%
controls:1.45%
14
28
242
2526
12
23
245
2541
7
8
250
2556
—
—
14
24
239
2509
23
34
212
2313
Office Visit
OMOP4822458 [581477]
7.6e-01
1.4e+00
2.1e+00
—
2.6e+00
1.6e+00
1.0e+00
cases:18.36%
controls:9.55%
cases:11.28%
controls:3.08%
cases:2.72%
controls:0.35%
—
—
cases:3.89%
controls:0.31%
cases:11.86%
controls:2.76%
cases:17.45%
controls:7.24%
47
244
209
2310
29
79
228
2485
7
9
250
2555
—
10
8
247
2552
30
70
223
2463
41
170
194
2177
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
1.5e+00
2.2e+00
—
—
—
2.8e+00
2.7e+00
cases:7.03%
controls:1.68%
cases:5.06%
controls:0.59%
—
—
—
—
—
—
cases:7.51%
controls:0.51%
cases:13.62%
controls:1.07%
18
43
238
2511
13
15
244
2549
—
—
—
19
13
234
2520
32
25
203
2322
FEV1
20150-9 [3024653]
1.5e+00
2.2e+00
—
—
—
2.8e+00
2.7e+00
cases:7.03%
controls:1.68%
cases:5.06%
controls:0.59%
—
—
—
—
—
—
cases:7.51%
controls:0.51%
cases:13.62%
controls:1.07%
18
43
238
2511
13
15
244
2549
—
—
—
19
13
234
2520
32
25
203
2322
FEV1/FVC
19926-5 [3011505]
1.5e+00
2.2e+00
—
—
—
2.8e+00
2.7e+00
cases:7.03%
controls:1.68%
cases:5.06%
controls:0.59%
—
—
—
—
—
—
cases:7.51%
controls:0.51%
cases:13.62%
controls:1.07%
18
43
238
2511
13
15
244
2549
—
—
—
19
13
234
2520
32
25
203
2322
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
9.3e-01
1.5e+00
2.1e+00
—
1.3e+00
1.6e+00
1.6e+00
cases:19.92%
controls:8.93%
cases:24.12%
controls:6.71%
cases:11.28%
controls:1.60%
—
—
cases:5.84%
controls:1.60%
cases:24.90%
controls:6.08%
cases:44.68%
controls:14.23%
51
228
205
2326
62
172
195
2392
29
41
228
2523
—
15
41
242
2519
63
154
190
2379
105
334
130
2013
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
8.5e-01
1.4e+00
2.3e+00
—
1.6e+00
1.3e+00
1.4e+00
cases:15.23%
controls:7.17%
cases:18.68%
controls:5.30%
cases:10.12%
controls:1.09%
—
—
cases:4.28%
controls:0.86%
cases:17.00%
controls:5.05%
cases:37.02%
controls:12.40%
39
183
217
2371
48
136
209
2428
26
28
231
2536
—
11
22
246
2538
43
128
210
2405
87
291
148
2056
doxycycline; oral, parenteral
J01AA02 [21602800]
1.0e+00
1.3e+00
2.0e+00
—
2.6e+00
1.0e+00
9.2e-01
cases:38.28%
controls:18.09%
cases:17.90%
controls:5.38%
cases:3.11%
controls:0.43%
—
—
cases:4.67%
controls:0.35%
cases:15.02%
controls:5.96%
cases:34.04%
controls:17.04%
98
462
158
2092
46
138
211
2426
8
11
249
2553
—
12
9
245
2551
38
151
215
2382
80
400
155
1947
Hypersensitivity skin testing
268377001 [4147813]
2.0e+00
2.5e+00
—
—
—
2.2e+00
2.2e+00
cases:4.30%
controls:0.63%
cases:2.72%
controls:0.23%
—
—
—
—
—
—
cases:3.16%
controls:0.36%
cases:5.96%
controls:0.68%
11
16
245
2538
7
6
250
2558
—
—
—
8
9
245
2524
14
16
221
2331
Emergency Room Visit
ER [9203]
1.1e+00
1.4e+00
1.9e+00
—
2.0e+00
1.2e+00
1.1e+00
cases:61.33%
controls:33.87%
cases:36.58%
controls:12.44%
cases:8.17%
controls:1.37%
—
—
cases:9.73%
controls:1.48%
cases:30.43%
controls:11.33%
cases:51.49%
controls:26.33%
157
865
99
1689
94
319
163
2245
21
35
236
2529
—
25
38
232
2522
77
287
176
2246
121
618
114
1729
Inpatient Hospital
21 [8717]
9.7e-01
1.3e+00
2.0e+00
—
2.1e+00
1.3e+00
1.0e+00
cases:52.34%
controls:29.33%
cases:27.63%
controls:9.63%
cases:7.39%
controls:1.09%
—
—
cases:6.23%
controls:0.78%
cases:24.51%
controls:8.25%
cases:40.85%
controls:20.32%
134
749
122
1805
71
247
186
2317
19
28
238
2536
—
16
20
241
2540
62
209
191
2324
96
477
139
1870
budesonide; oral, sublingual
A07EA06 [21600658]
2.5e+00
—
—
—
—
2.8e+00
3.0e+00
cases:4.30%
controls:0.35%
—
—
—
—
—
—
—
—
cases:3.16%
controls:0.20%
cases:4.68%
controls:0.26%
11
9
245
2545
—
—
—
—
8
5
245
2528
11
6
224
2341
Short blood count panel - Blood
55429-5 [40758558]
8.6e-01
1.3e+00
1.6e+00
—
1.9e+00
1.1e+00
1.6e+00
cases:10.94%
controls:4.93%
cases:10.51%
controls:3.12%
cases:3.50%
controls:0.74%
—
—
cases:3.89%
controls:0.63%
cases:8.30%
controls:2.88%
cases:20.00%
controls:4.90%
28
126
228
2428
27
80
230
2484
9
19
248
2545
—
10
16
247
2544
21
73
232
2460
47
115
188
2232
Nonallergic asthma
J45.1 [45557625]
1.8e+00
2.0e+00
—
1.0e+50
—
2.4e+00
2.0e+00
cases:6.64%
controls:1.17%
cases:5.45%
controls:0.78%
—
—
cases:2.72%
controls:0.00%
—
—
cases:7.11%
controls:0.67%
cases:8.09%
controls:1.19%
17
30
239
2524
14
20
243
2544
—
7
0
250
2564
—
18
17
235
2516
19
28
216
2319
Oedema, unspecified
R60.9 [45568143]
2.7e+00
—
—
—
1.0e+50
2.6e+00
2.8e+00
cases:5.08%
controls:0.35%
—
—
—
—
—
—
cases:1.95%
controls:0.00%
cases:3.16%
controls:0.24%
cases:5.11%
controls:0.34%
13
9
243
2545
—
—
—
5
0
252
2560
8
6
245
2527
12
8
223
2339
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.8e+00
2.3e+00
—
—
—
2.1e+00
1.9e+00
cases:7.03%
controls:1.25%
cases:5.45%
controls:0.55%
—
—
—
—
—
—
cases:3.95%
controls:0.51%
cases:9.36%
controls:1.58%
18
32
238
2522
14
14
243
2550
—
—
—
10
13
243
2520
22
37
213
2310
prednisone
A07EA03 [21600655]
1.8e+00
2.0e+00
—
—
—
2.4e+00
1.7e+00
cases:7.81%
controls:1.33%
cases:3.50%
controls:0.47%
—
—
—
—
—
—
cases:3.95%
controls:0.36%
cases:6.38%
controls:1.19%
20
34
236
2520
9
12
248
2552
—
—
—
10
9
243
2524
15
28
220
2319
prednisone; oral
H02AB07 [21602735]
1.8e+00
2.0e+00
—
—
—
2.4e+00
1.7e+00
cases:7.81%
controls:1.33%
cases:3.50%
controls:0.47%
—
—
—
—
—
—
cases:3.95%
controls:0.36%
cases:6.38%
controls:1.19%
20
34
236
2520
9
12
248
2552
—
—
—
10
9
243
2524
15
28
220
2319
Upper gastrointestinal surgery
106 [44777669]
1.1e+00
1.4e+00
1.7e+00
—
2.9e+00
1.5e+00
1.1e+00
cases:16.41%
controls:6.34%
cases:10.51%
controls:2.69%
cases:1.95%
controls:0.35%
—
—
cases:3.50%
controls:0.20%
cases:9.88%
controls:2.33%
cases:20.00%
controls:7.71%
42
162
214
2392
27
69
230
2495
5
9
252
2555
—
9
5
248
2555
25
59
228
2474
47
181
188
2166
Emergency Medicine
93 [38004510]
1.0e+00
1.4e+00
1.6e+00
1.0e+50
1.9e+00
1.4e+00
6.8e-01
cases:20.70%
controls:8.69%
cases:17.90%
controls:5.03%
cases:3.50%
controls:0.74%
cases:3.50%
controls:0.00%
cases:5.84%
controls:0.90%
cases:21.34%
controls:6.32%
cases:32.77%
controls:19.77%
53
222
203
2332
46
129
211
2435
9
19
248
2545
9
0
248
2564
15
23
242
2537
54
160
199
2373
77
464
158
1883
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.1e+00
1.5e+00
2.3e+00
—
1.3e+00
1.5e+00
1.6e+00
cases:12.50%
controls:4.42%
cases:14.01%
controls:3.55%
cases:7.00%
controls:0.78%
—
—
cases:1.95%
controls:0.55%
cases:14.62%
controls:3.67%
cases:29.36%
controls:8.05%
32
113
224
2441
36
91
221
2473
18
20
239
2544
—
5
14
252
2546
37
93
216
2440
69
189
166
2158
hydroxychloroquine; oral
P01BA02 [21604889]
2.1e+00
2.0e+00
—
—
2.3e+00
1.9e+00
1.8e+00
cases:7.42%
controls:0.98%
cases:5.84%
controls:0.82%
—
—
—
—
cases:1.95%
controls:0.20%
cases:5.53%
controls:0.83%
cases:6.38%
controls:1.07%
19
25
237
2529
15
21
242
2543
—
—
5
5
252
2555
14
21
239
2512
15
25
220
2322
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
7.2e-01
9.3e-01
2.0e+00
—
2.2e+00
1.1e+00
9.6e-01
cases:15.63%
controls:8.26%
cases:11.67%
controls:4.95%
cases:3.50%
controls:0.51%
—
—
cases:4.67%
controls:0.55%
cases:13.04%
controls:4.82%
cases:28.09%
controls:13.00%
40
211
216
2343
30
127
227
2437
9
13
248
2551
—
12
14
245
2546
33
122
220
2411
66
305
169
2042
Normoblasts [#/volume] in Blood
715-3 [3021589]
6.4e-01
1.1e+00
2.1e+00
—
1.8e+00
1.2e+00
1.4e+00
cases:11.72%
controls:6.54%
cases:15.18%
controls:5.42%
cases:7.39%
controls:0.94%
—
—
cases:5.45%
controls:0.94%
cases:15.42%
controls:5.21%
cases:34.04%
controls:10.91%
30
167
226
2387
39
139
218
2425
19
24
238
2540
—
14
24
243
2536
39
132
214
2401
80
256
155
2091
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.8e+00
2.2e+00
—
—
—
1.9e+00
1.8e+00
cases:7.03%
controls:1.21%
cases:5.45%
controls:0.66%
—
—
—
—
—
—
cases:5.93%
controls:0.91%
cases:12.77%
controls:2.47%
18
31
238
2523
14
17
243
2547
—
—
—
15
23
238
2510
30
58
205
2289
Fever, unspecified
R50.9 [45582716]
1.6e+00
2.2e+00
—
—
—
2.3e+00
1.6e+00
cases:7.42%
controls:1.61%
cases:6.61%
controls:0.78%
—
—
—
—
—
—
cases:4.74%
controls:0.51%
cases:10.64%
controls:2.43%
19
41
237
2513
17
20
240
2544
—
—
—
12
13
241
2520
25
57
210
2290
desloratadine; oral
R06AX27 [21603526]
8.7e-01
1.8e+00
1.5e+00
—
2.3e+00
1.4e+00
1.2e+00
cases:15.23%
controls:7.01%
cases:15.18%
controls:2.93%
cases:2.33%
controls:0.51%
—
—
cases:4.28%
controls:0.43%
cases:11.86%
controls:3.08%
cases:20.85%
controls:7.67%
39
179
217
2375
39
75
218
2489
6
13
251
2551
—
11
11
246
2549
30
78
223
2455
49
180
186
2167
pregabalin; oral
N02BF02 [955152]
1.3e+00
1.3e+00
1.7e+00
—
1.2e+00
1.7e+00
1.5e+00
cases:11.33%
controls:3.21%
cases:5.45%
controls:1.52%
cases:3.11%
controls:0.59%
—
—
cases:1.95%
controls:0.59%
cases:7.11%
controls:1.42%
cases:13.62%
controls:3.37%
29
82
227
2472
14
39
243
2525
8
15
249
2549
—
5
15
252
2545
18
36
235
2497
32
79
203
2268
Prick test
37968009 [4242723]
1.4e+00
2.7e+00
—
—
—
2.2e+00
2.6e+00
cases:3.52%
controls:0.90%
cases:4.67%
controls:0.31%
—
—
—
—
—
—
cases:3.16%
controls:0.36%
cases:6.81%
controls:0.55%
9
23
247
2531
12
8
245
2556
—
—
—
8
9
245
2524
16
13
219
2334
Teaching
WZC30 [2001310891]
1.3e+00
2.1e+00
—
—
—
2.3e+00
1.8e+00
cases:5.86%
controls:1.64%
cases:5.84%
controls:0.74%
—
—
—
—
—
—
cases:5.93%
controls:0.63%
cases:11.06%
controls:2.05%
15
42
241
2512
15
19
242
2545
—
—
—
15
16
238
2517
26
48
209
2299
Exposure to unspecified factor
X59 [45756412]
1.4e+00
2.1e+00
—
—
—
2.3e+00
1.6e+00
cases:7.42%
controls:1.96%
cases:6.61%
controls:0.82%
—
—
—
—
—
—
cases:6.72%
controls:0.71%
cases:11.06%
controls:2.34%
19
50
237
2504
17
21
240
2543
—
—
—
17
18
236
2515
26
55
209
2292
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
1.3e+00
1.6e+00
2.1e+00
—
1.7e+00
1.4e+00
1.0e+00
cases:12.50%
controls:3.64%
cases:10.51%
controls:2.30%
cases:3.11%
controls:0.39%
—
—
cases:1.95%
controls:0.35%
cases:9.09%
controls:2.49%
cases:18.72%
controls:7.50%
32
93
224
2461
27
59
230
2505
8
10
249
2554
—
5
9
252
2551
23
63
230
2470
44
176
191
2171
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
5.1e-01
1.0e+00
2.0e+00
—
1.9e+00
1.1e+00
8.3e-01
cases:30.86%
controls:21.06%
cases:32.30%
controls:14.55%
cases:16.73%
controls:2.57%
—
—
cases:14.01%
controls:2.30%
cases:34.39%
controls:15.12%
cases:56.17%
controls:35.83%
79
538
177
2016
83
373
174
2191
43
66
214
2498
—
36
59
221
2501
87
383
166
2150
132
841
103
1506
hydrocortisone; oral, parenteral
H02AB09 [21602737]
1.8e+00
2.1e+00
—
—
—
1.7e+00
1.8e+00
cases:8.20%
controls:1.45%
cases:4.67%
controls:0.62%
—
—
—
—
—
—
cases:3.95%
controls:0.75%
cases:8.09%
controls:1.36%
21
37
235
2517
12
16
245
2548
—
—
—
10
19
243
2514
19
32
216
2315
Remote contact by phone
ZYC01 [2001311579]
—
2.3e+00
—
—
—
2.5e+00
2.5e+00
—
—
cases:3.11%
controls:0.31%
—
—
—
—
—
—
cases:2.37%
controls:0.20%
cases:5.96%
controls:0.51%
—
8
8
249
2556
—
—
—
6
5
247
2528
14
12
221
2335
valaciclovir; oral
J05AB11 [21603137]
1.3e+00
2.4e+00
2.3e+00
—
—
2.2e+00
1.5e+00
cases:5.86%
controls:1.68%
cases:6.61%
controls:0.66%
cases:1.95%
controls:0.20%
—
—
—
—
cases:5.53%
controls:0.63%
cases:9.36%
controls:2.34%
15
43
241
2511
17
17
240
2547
5
5
252
2559
—
—
14
16
239
2517
22
55
213
2292
Thorax X-ray examination
GD1AA [2001303617]
1.3e+00
1.9e+00
—
1.0e+50
1.7e+00
2.3e+00
1.8e+00
cases:20.31%
controls:6.38%
cases:14.79%
controls:2.54%
—
—
cases:1.95%
controls:0.00%
cases:1.95%
controls:0.35%
cases:15.42%
controls:1.86%
cases:28.09%
controls:6.09%
52
163
204
2391
38
65
219
2499
—
5
0
252
2564
5
9
252
2551
39
47
214
2486
66
143
169
2204
mesalazine; oral, rectal
A07EC02 [21600664]
1.5e+00
1.6e+00
2.5e+00
—
—
1.8e+00
1.5e+00
cases:4.30%
controls:0.98%
cases:2.72%
controls:0.59%
cases:2.33%
controls:0.20%
—
—
—
—
cases:3.56%
controls:0.63%
cases:4.26%
controls:0.98%
11
25
245
2529
7
15
250
2549
6
5
251
2559
—
—
9
16
244
2517
10
23
225
2324
moxifloxacin; oral, parenteral
J01MA14 [21603021]
2.4e+00
—
—
—
—
2.8e+00
2.0e+00
cases:5.47%
controls:0.51%
—
—
—
—
—
—
—
—
cases:3.95%
controls:0.24%
cases:5.96%
controls:0.85%
14
13
242
2541
—
—
—
—
10
6
243
2527
14
20
221
2327
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
8.2e-01
1.6e+00
2.4e+00
—
1.3e+00
1.4e+00
1.1e+00
cases:24.22%
controls:12.33%
cases:26.07%
controls:6.63%
cases:10.51%
controls:1.09%
—
—
cases:3.89%
controls:1.09%
cases:22.92%
controls:7.07%
cases:44.26%
controls:20.66%
62
315
194
2239
67
170
190
2394
27
28
230
2536
—
10
28
247
2532
58
179
195
2354
104
485
131
1862
spironolactone; oral
C03DA01 [21601534]
2.0e+00
1.9e+00
—
—
—
1.6e+00
1.7e+00
cases:5.47%
controls:0.78%
cases:4.67%
controls:0.70%
—
—
—
—
—
—
cases:4.35%
controls:0.87%
cases:7.23%
controls:1.45%
14
20
242
2534
12
18
245
2546
—
—
—
11
22
242
2511
17
34
218
2313
cetirizine; oral
R06AE07 [21603497]
1.2e+00
1.6e+00
2.0e+00
—
1.6e+00
1.3e+00
1.1e+00
cases:23.83%
controls:8.73%
cases:15.56%
controls:3.67%
cases:3.11%
controls:0.43%
—
—
cases:2.72%
controls:0.55%
cases:13.04%
controls:3.95%
cases:23.83%
controls:9.03%
61
223
195
2331
40
94
217
2470
8
11
249
2553
—
7
14
250
2546
33
100
220
2433
56
212
179
2135
roxithromycin; oral
J01FA06 [21602974]
1.3e+00
2.4e+00
—
—
—
2.0e+00
1.5e+00
cases:13.67%
controls:4.15%
cases:7.78%
controls:0.78%
—
—
—
—
—
—
cases:6.32%
controls:0.91%
cases:12.34%
controls:2.94%
35
106
221
2448
20
20
237
2544
—
—
—
16
23
237
2510
29
69
206
2278
Coloscopy
UJF32 [2001305029]
1.6e+00
2.1e+00
—
—
—
1.8e+00
1.6e+00
cases:10.55%
controls:2.35%
cases:5.45%
controls:0.70%
—
—
—
—
—
—
cases:4.74%
controls:0.79%
cases:13.62%
controls:3.03%
27
60
229
2494
14
18
243
2546
—
—
—
12
20
241
2513
32
71
203
2276
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.3e+00
2.0e+00
—
—
—
2.0e+00
1.8e+00
cases:12.89%
controls:3.92%
cases:8.56%
controls:1.25%
—
—
—
—
—
—
cases:6.72%
controls:0.99%
cases:16.60%
controls:3.20%
33
100
223
2454
22
32
235
2532
—
—
—
17
25
236
2508
39
75
196
2272
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
9.6e-01
1.3e+00
1.6e+00
—
2.2e+00
1.2e+00
1.3e+00
cases:10.55%
controls:4.31%
cases:9.73%
controls:2.73%
cases:2.72%
controls:0.59%
—
—
cases:2.72%
controls:0.31%
cases:9.09%
controls:2.80%
cases:22.98%
controls:7.37%
27
110
229
2444
25
70
232
2494
7
15
250
2549
—
7
8
250
2552
23
71
230
2462
54
173
181
2174
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.3e-01
1.2e+00
1.8e+00
—
1.6e+00
1.2e+00
1.3e+00
cases:18.75%
controls:11.98%
cases:23.35%
controls:8.07%
cases:8.17%
controls:1.52%
—
—
cases:6.61%
controls:1.41%
cases:23.72%
controls:8.72%
cases:45.53%
controls:19.09%
48
306
208
2248
60
207
197
2357
21
39
236
2525
—
17
36
240
2524
60
221
193
2312
107
448
128
1899
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
6.8e-01
1.4e+00
1.6e+00
—
1.6e+00
1.3e+00
1.1e+00
cases:12.50%
controls:6.77%
cases:13.62%
controls:3.86%
cases:3.50%
controls:0.70%
—
—
cases:3.50%
controls:0.70%
cases:12.25%
controls:3.75%
cases:29.36%
controls:12.23%
32
173
224
2381
35
99
222
2465
9
18
248
2546
—
9
18
248
2542
31
95
222
2438
69
287
166
2060
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
1.1e+00
1.4e+00
2.2e+00
—
1.6e+00
1.4e+00
7.7e-01
cases:15.23%
controls:5.48%
cases:12.06%
controls:3.20%
cases:3.89%
controls:0.43%
—
—
cases:2.33%
controls:0.47%
cases:10.67%
controls:2.88%
cases:21.70%
controls:11.42%
39
140
217
2414
31
82
226
2482
10
11
247
2553
—
6
12
251
2548
27
73
226
2460
51
268
184
2079
Platelets [#/volume] in Blood
26515-7 [3007461]
1.5e-01
5.6e-01
1.4e+00
3.1e+00
1.2e+00
5.9e-01
4.5e-01
cases:30.47%
controls:27.45%
cases:35.80%
controls:24.18%
cases:19.07%
controls:5.30%
cases:4.28%
controls:0.20%
cases:14.01%
controls:4.77%
cases:37.55%
controls:25.03%
cases:62.13%
controls:51.04%
78
701
178
1853
92
620
165
1944
49
136
208
2428
11
5
246
2559
36
122
221
2438
95
634
158
1899
146
1198
89
1149
MCH [Entitic mass]
28539-5 [3035941]
1.5e-01
5.5e-01
1.4e+00
3.1e+00
1.2e+00
5.9e-01
4.4e-01
cases:30.47%
controls:27.49%
cases:35.80%
controls:24.26%
cases:19.07%
controls:5.30%
cases:4.28%
controls:0.20%
cases:14.01%
controls:4.77%
cases:37.55%
controls:24.99%
cases:62.13%
controls:51.30%
78
702
178
1852
92
622
165
1942
49
136
208
2428
11
5
246
2559
36
122
221
2438
95
633
158
1900
146
1204
89
1143
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.5e-01
5.5e-01
1.4e+00
3.1e+00
1.2e+00
5.9e-01
4.4e-01
cases:30.47%
controls:27.49%
cases:35.80%
controls:24.26%
cases:19.07%
controls:5.30%
cases:4.28%
controls:0.20%
cases:14.01%
controls:4.77%
cases:37.55%
controls:25.03%
cases:62.13%
controls:51.30%
78
702
178
1852
92
622
165
1942
49
136
208
2428
11
5
246
2559
36
122
221
2438
95
634
158
1899
146
1204
89
1143
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.5e-01
5.5e-01
1.4e+00
3.1e+00
1.2e+00
5.9e-01
4.4e-01
cases:30.47%
controls:27.49%
cases:35.80%
controls:24.26%
cases:19.07%
controls:5.30%
cases:4.28%
controls:0.20%
cases:14.01%
controls:4.77%
cases:37.55%
controls:25.03%
cases:62.13%
controls:51.26%
78
702
178
1852
92
622
165
1942
49
136
208
2428
11
5
246
2559
36
122
221
2438
95
634
158
1899
146
1203
89
1144
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.6e-01
5.5e-01
1.4e+00
3.1e+00
1.2e+00
5.8e-01
4.4e-01
cases:30.86%
controls:27.49%
cases:35.80%
controls:24.26%
cases:19.07%
controls:5.30%
cases:4.28%
controls:0.20%
cases:14.01%
controls:4.77%
cases:37.55%
controls:25.11%
cases:62.13%
controls:51.47%
79
702
177
1852
92
622
165
1942
49
136
208
2428
11
5
246
2559
36
122
221
2438
95
636
158
1897
146
1208
89
1139
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.5e-01
5.5e-01
1.4e+00
3.1e+00
1.1e+00
5.9e-01
4.4e-01
cases:30.47%
controls:27.49%
cases:35.80%
controls:24.26%
cases:19.07%
controls:5.30%
cases:4.28%
controls:0.20%
cases:13.62%
controls:4.77%
cases:37.55%
controls:24.99%
cases:62.13%
controls:51.26%
78
702
178
1852
92
622
165
1942
49
136
208
2428
11
5
246
2559
35
122
222
2438
95
633
158
1900
146
1203
89
1144
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.4e-01
5.5e-01
1.4e+00
3.0e+00
1.2e+00
5.9e-01
4.4e-01
cases:30.47%
controls:27.53%
cases:35.80%
controls:24.38%
cases:19.07%
controls:5.34%
cases:3.89%
controls:0.20%
cases:14.01%
controls:4.77%
cases:37.55%
controls:25.07%
cases:62.13%
controls:51.38%
78
703
178
1851
92
625
165
1939
49
137
208
2427
10
5
247
2559
36
122
221
2438
95
635
158
1898
146
1206
89
1141
Essential (primary) hypertension
I10 [45591453]
6.8e-01
1.1e+00
1.5e+00
—
1.7e+00
1.1e+00
6.8e-01
cases:17.19%
controls:9.55%
cases:14.40%
controls:5.23%
cases:3.89%
controls:0.90%
—
—
cases:4.67%
controls:0.86%
cases:12.65%
controls:4.74%
cases:25.11%
controls:14.49%
44
244
212
2310
37
134
220
2430
10
23
247
2541
—
12
22
245
2538
32
120
221
2413
59
340
176
2007
Chronic rhinitis
J31.0 [45572165]
2.2e+00
2.1e+00
—
—
—
2.8e+00
1.8e+00
cases:5.08%
controls:0.59%
cases:1.95%
controls:0.23%
—
—
—
—
—
—
cases:4.74%
controls:0.32%
cases:5.96%
controls:1.02%
13
15
243
2539
5
6
252
2558
—
—
—
12
8
241
2525
14
24
221
2323
Outpatient Hospital
22 [8756]
9.6e-01
1.2e+00
1.5e+00
—
2.3e+00
1.3e+00
9.3e-01
cases:44.53%
controls:23.45%
cases:19.46%
controls:6.79%
cases:3.11%
controls:0.70%
—
—
cases:3.89%
controls:0.39%
cases:20.55%
controls:6.36%
cases:33.19%
controls:16.45%
114
599
142
1955
50
174
207
2390
8
18
249
2546
—
10
10
247
2550
52
161
201
2372
78
386
157
1961
Pneumonia, unspecified
J18.9 [45601123]
1.6e+00
2.2e+00
—
—
—
1.7e+00
1.2e+00
cases:8.20%
controls:1.80%
cases:8.17%
controls:0.94%
—
—
—
—
—
—
cases:3.95%
controls:0.75%
cases:9.79%
controls:3.11%
21
46
235
2508
21
24
236
2540
—
—
—
10
19
243
2514
23
73
212
2274
Rhinopharyngoscopy
UDH02 [2001301680]
1.7e+00
2.8e+00
—
—
—
1.9e+00
2.2e+00
cases:3.91%
controls:0.74%
cases:3.11%
controls:0.20%
—
—
—
—
—
—
cases:2.37%
controls:0.36%
cases:3.83%
controls:0.43%
10
19
246
2535
8
5
249
2559
—
—
—
6
9
247
2524
9
10
226
2337
fluconazole; oral, parenteral
J02AC01 [21603080]
7.4e-01
1.3e+00
1.6e+00
—
2.2e+00
1.5e+00
9.3e-01
cases:16.02%
controls:8.34%
cases:10.12%
controls:2.93%
cases:1.95%
controls:0.39%
—
—
cases:3.11%
controls:0.35%
cases:11.86%
controls:2.88%
cases:17.87%
controls:7.88%
41
213
215
2341
26
75
231
2489
5
10
252
2554
—
8
9
249
2551
30
73
223
2460
42
185
193
2162
budesonide; inhalant
R03BA02 [21603285]
1.4e+00
1.3e+00
1.4e+00
—
1.6e+00
1.3e+00
1.1e+00
cases:17.19%
controls:4.93%
cases:11.28%
controls:3.32%
cases:2.72%
controls:0.66%
—
—
cases:3.89%
controls:0.78%
cases:10.67%
controls:3.28%
cases:14.89%
controls:5.45%
44
126
212
2428
29
85
228
2479
7
17
250
2547
—
10
20
247
2540
27
83
226
2450
35
128
200
2219
Cathetrisation of vein
TPH04 [2001309597]
1.2e+00
1.5e+00
—
—
—
2.1e+00
1.9e+00
cases:6.25%
controls:1.96%
cases:3.50%
controls:0.78%
—
—
—
—
—
—
cases:4.74%
controls:0.63%
cases:14.04%
controls:2.47%
16
50
240
2504
9
20
248
2544
—
—
—
12
16
241
2517
33
58
202
2289
Supplier / Service Provider
OMOP5117446 [33004]
-3.8e-01
-4.0e-01
—
—
—
3.2e+00
3.4e+00
cases:17.58%
controls:23.84%
cases:7.00%
controls:10.14%
—
—
—
—
—
—
cases:11.07%
controls:0.51%
cases:25.11%
controls:1.07%
45
609
211
1945
18
260
239
2304
—
—
—
28
13
225
2520
59
25
176
2322
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
8.3e-01
1.5e+00
—
—
2.3e+00
1.1e+00
8.8e-01
cases:9.77%
controls:4.50%
cases:9.73%
controls:2.38%
—
—
—
—
cases:3.11%
controls:0.31%
cases:6.72%
controls:2.37%
cases:16.17%
controls:7.41%
25
115
231
2439
25
61
232
2503
—
—
8
8
249
2552
17
60
236
2473
38
174
197
2173
Microorganisms panel - Urine sediment
58435-9 [40761536]
2.0e+00
1.8e+00
—
—
—
1.6e+00
1.2e+00
cases:5.08%
controls:0.70%
cases:3.50%
controls:0.62%
—
—
—
—
—
—
cases:3.16%
controls:0.63%
cases:5.96%
controls:1.92%
13
18
243
2536
9
16
248
2548
—
—
—
8
16
245
2517
14
45
221
2302
Physiotherapist
Z3226 [2001311560]
1.0e+00
1.7e+00
—
—
—
1.9e+00
1.8e+00
cases:9.77%
controls:3.68%
cases:7.00%
controls:1.37%
—
—
—
—
—
—
cases:7.51%
controls:1.14%
cases:11.06%
controls:1.96%
25
94
231
2460
18
35
239
2529
—
—
—
19
29
234
2504
26
46
209
2301
Ophthalmology
18 [38004463]
7.0e-01
8.9e-01
1.5e+00
—
1.7e+00
8.8e-01
8.5e-01
cases:19.14%
controls:10.53%
cases:12.06%
controls:5.34%
cases:3.89%
controls:0.90%
—
—
cases:3.89%
controls:0.74%
cases:13.44%
controls:6.04%
cases:25.96%
controls:13.08%
49
269
207
2285
31
137
226
2427
10
23
247
2541
—
10
19
247
2541
34
153
219
2380
61
307
174
2040
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
9.7e-01
1.2e+00
—
—
2.3e+00
1.3e+00
1.6e+00
cases:5.86%
controls:2.31%
cases:5.06%
controls:1.64%
—
—
—
—
cases:2.72%
controls:0.27%
cases:5.53%
controls:1.50%
cases:14.47%
controls:3.15%
15
59
241
2495
13
42
244
2522
—
—
7
7
250
2553
14
38
239
2495
34
74
201
2273
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
—
2.3e+00
—
—
1.0e+50
2.0e+00
2.1e+00
—
—
cases:2.72%
controls:0.27%
—
—
—
—
cases:1.95%
controls:0.00%
cases:3.95%
controls:0.55%
cases:6.81%
controls:0.85%
—
7
7
250
2557
—
—
5
0
252
2560
10
14
243
2519
16
20
219
2327
antibiotics in combination with corticosteroids
D01AA20 [21601918]
1.3e+00
2.0e+00
—
—
—
1.7e+00
1.4e+00
cases:5.47%
controls:1.49%
cases:3.50%
controls:0.47%
—
—
—
—
—
—
cases:3.56%
controls:0.67%
cases:5.96%
controls:1.58%
14
38
242
2516
9
12
248
2552
—
—
—
9
17
244
2516
14
37
221
2310
Bacteria identified in Blood by Culture
600-7 [3023368]
1.1e+00
1.9e+00
—
—
—
1.8e+00
1.5e+00
cases:7.42%
controls:2.58%
cases:8.17%
controls:1.33%
—
—
—
—
—
—
cases:7.91%
controls:1.38%
cases:15.32%
controls:3.88%
19
66
237
2488
21
34
236
2530
—
—
—
20
35
233
2498
36
91
199
2256
Gastroenterology
10 [38004455]
1.2e+00
1.5e+00
—
—
—
1.8e+00
1.7e+00
cases:12.11%
controls:3.92%
cases:7.00%
controls:1.68%
—
—
—
—
—
—
cases:9.49%
controls:1.66%
cases:21.70%
controls:4.69%
31
100
225
2454
18
43
239
2521
—
—
—
24
42
229
2491
51
110
184
2237
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.0e+00
1.4e+00
1.9e+00
—
1.6e+00
1.2e+00
6.9e-01
cases:15.63%
controls:6.30%
cases:13.62%
controls:3.78%
cases:3.89%
controls:0.62%
—
—
cases:2.72%
controls:0.59%
cases:12.25%
controls:3.91%
cases:25.96%
controls:14.91%
40
161
216
2393
35
97
222
2467
10
16
247
2548
—
7
15
250
2545
31
99
222
2434
61
350
174
1997
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
1.0e+00
1.4e+00
1.9e+00
—
1.5e+00
1.2e+00
6.9e-01
cases:15.63%
controls:6.38%
cases:13.62%
controls:3.78%
cases:3.89%
controls:0.62%
—
—
cases:2.72%
controls:0.63%
cases:12.25%
controls:3.91%
cases:25.96%
controls:15.00%
40
163
216
2391
35
97
222
2467
10
16
247
2548
—
7
16
250
2544
31
99
222
2434
61
352
174
1995
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
1.0e+00
1.4e+00
1.9e+00
—
1.6e+00
1.2e+00
7.0e-01
cases:15.23%
controls:6.19%
cases:13.62%
controls:3.78%
cases:3.89%
controls:0.62%
—
—
cases:2.72%
controls:0.59%
cases:11.86%
controls:3.87%
cases:25.53%
controls:14.57%
39
158
217
2396
35
97
222
2467
10
16
247
2548
—
7
15
250
2545
30
98
223
2435
60
342
175
2005
vilanterol and fluticasone furoate
R03AK10 [43534841]
1.7e+00
2.2e+00
—
—
—
2.0e+00
2.0e+00
cases:1.95%
controls:0.35%
cases:2.33%
controls:0.27%
—
—
—
—
—
—
cases:2.77%
controls:0.39%
cases:4.26%
controls:0.60%
5
9
251
2545
6
7
251
2557
—
—
—
7
10
246
2523
10
14
225
2333
furosemide; oral, parenteral
C03CA01 [21601518]
1.5e+00
1.6e+00
1.2e+00
—
—
1.5e+00
1.5e+00
cases:12.50%
controls:2.98%
cases:8.95%
controls:1.95%
cases:2.33%
controls:0.74%
—
—
—
—
cases:8.70%
controls:2.17%
cases:12.34%
controls:3.03%
32
76
224
2478
23
50
234
2514
6
19
251
2545
—
—
22
55
231
2478
29
71
206
2276
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
2.6e+00
—
—
—
—
—
3.5e+00
cases:3.13%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:9.79%
controls:0.34%
8
6
248
2548
—
—
—
—
—
23
8
212
2339
Psychiatry
26 [38004469]
1.0e+00
1.2e+00
8.6e-01
—
1.3e+00
1.3e+00
1.3e+00
cases:14.06%
controls:5.64%
cases:10.12%
controls:3.43%
cases:3.89%
controls:1.68%
—
—
cases:5.45%
controls:1.56%
cases:10.28%
controls:3.12%
cases:21.28%
controls:6.86%
36
144
220
2410
26
88
231
2476
10
43
247
2521
—
14
40
243
2520
26
79
227
2454
50
161
185
2186
pH of Urine
2756-5 [3015736]
8.9e-01
1.4e+00
1.8e+00
—
1.5e+00
1.1e+00
6.9e-01
cases:12.11%
controls:5.36%
cases:10.51%
controls:2.69%
cases:3.11%
controls:0.51%
—
—
cases:1.95%
controls:0.43%
cases:8.70%
controls:3.04%
cases:20.43%
controls:11.42%
31
137
225
2417
27
69
230
2495
8
13
249
2551
—
5
11
252
2549
22
77
231
2456
48
268
187
2079
Scheduled procedure
ZXD10 [2001311387]
8.8e-01
1.3e+00
—
—
—
2.0e+00
1.8e+00
cases:14.06%
controls:6.34%
cases:7.39%
controls:2.03%
—
—
—
—
—
—
cases:8.70%
controls:1.30%
cases:14.89%
controls:2.94%
36
162
220
2392
19
52
238
2512
—
—
—
22
33
231
2500
35
69
200
2278
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
2.5e+00
—
1.0e+50
1.0e+50
—
—
3.4e+00
cases:5.47%
controls:0.47%
—
—
cases:7.39%
controls:0.00%
cases:3.89%
controls:0.00%
—
—
—
—
cases:11.49%
controls:0.43%
14
12
242
2542
—
19
0
238
2564
10
0
247
2564
—
—
27
10
208
2337
Hematology
82 [38004501]
1.3e+00
2.0e+00
—
—
—
2.0e+00
1.9e+00
cases:2.73%
controls:0.74%
cases:2.72%
controls:0.39%
—
—
—
—
—
—
cases:2.77%
controls:0.39%
cases:5.11%
controls:0.77%
7
19
249
2535
7
10
250
2554
—
—
—
7
10
246
2523
12
18
223
2329
Ultrasound examination of lower leg veins
PH2AE [2001309451]
1.4e+00
1.4e+00
—
—
—
2.3e+00
2.1e+00
cases:4.30%
controls:1.06%
cases:1.95%
controls:0.51%
—
—
—
—
—
—
cases:2.37%
controls:0.24%
cases:6.81%
controls:0.89%
11
27
245
2527
5
13
252
2551
—
—
—
6
6
247
2527
16
21
219
2326
IgG subclass 4 [Mass/volume] in Serum
2469-5 [3024980]
2.8e+00
—
—
—
—
—
3.1e+00
cases:3.13%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
cases:5.96%
controls:0.30%
8
5
248
2549
—
—
—
—
—
14
7
221
2340
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
2.5e+00
—
1.0e+50
1.0e+50
—
—
3.3e+00
cases:5.47%
controls:0.47%
—
—
cases:6.61%
controls:0.00%
cases:3.50%
controls:0.00%
—
—
—
—
cases:11.49%
controls:0.47%
14
12
242
2542
—
17
0
240
2564
9
0
248
2564
—
—
27
11
208
2336
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
6.6e-01
1.9e+00
—
—
—
2.3e+00
1.6e+00
cases:1.95%
controls:1.02%
cases:3.89%
controls:0.59%
—
—
—
—
—
—
cases:4.35%
controls:0.47%
cases:9.79%
controls:2.13%
5
26
251
2528
10
15
247
2549
—
—
—
11
12
242
2521
23
50
212
2297
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
1.2e+00
2.2e+00
—
—
—
2.2e+00
1.4e+00
cases:2.34%
controls:0.70%
cases:4.28%
controls:0.51%
—
—
—
—
—
—
cases:2.77%
controls:0.32%
cases:5.11%
controls:1.28%
6
18
250
2536
11
13
246
2551
—
—
—
7
8
246
2525
12
30
223
2317
Cardiology
6 [38004451]
7.1e-01
1.2e+00
—
—
2.3e+00
1.3e+00
9.7e-01
cases:11.33%
controls:5.91%
cases:8.17%
controls:2.61%
—
—
—
—
cases:2.33%
controls:0.23%
cases:9.49%
controls:2.88%
cases:18.30%
controls:7.80%
29
151
227
2403
21
67
236
2497
—
—
6
6
251
2554
24
73
229
2460
43
183
192
2164
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
1.2e+00
2.0e+00
—
—
—
2.2e+00
1.5e+00
cases:2.34%
controls:0.74%
cases:3.89%
controls:0.55%
—
—
—
—
—
—
cases:3.95%
controls:0.43%
cases:6.81%
controls:1.62%
6
19
250
2535
10
14
247
2550
—
—
—
10
11
243
2522
16
38
219
2309
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.3e+00
1.3e+00
—
—
—
1.8e+00
1.3e+00
cases:14.84%
controls:4.54%
cases:5.06%
controls:1.44%
—
—
—
—
—
—
cases:5.93%
controls:1.03%
cases:12.77%
controls:3.75%
38
116
218
2438
13
37
244
2527
—
—
—
15
26
238
2507
30
88
205
2259
Sleep apnoea
G47.3 [45562094]
6.8e-01
1.1e+00
2.2e+00
—
—
1.3e+00
1.1e+00
cases:5.47%
controls:2.86%
cases:5.45%
controls:1.79%
cases:2.33%
controls:0.27%
—
—
—
—
cases:6.32%
controls:1.74%
cases:11.06%
controls:4.13%
14
73
242
2481
14
46
243
2518
6
7
251
2557
—
—
16
44
237
2489
26
97
209
2250
Laboratory Visit
OMOP4822461 [32036]
9.9e-02
3.0e-01
1.3e+00
3.4e+00
1.0e+00
3.4e-01
2.4e-01
cases:33.98%
controls:31.79%
cases:38.91%
controls:32.02%
cases:28.02%
controls:9.91%
cases:10.89%
controls:0.39%
cases:22.18%
controls:9.41%
cases:42.29%
controls:34.27%
cases:66.38%
controls:60.76%
87
812
169
1742
100
821
157
1743
72
254
185
2310
28
10
229
2554
57
241
200
2319
107
868
146
1665
156
1426
79
921
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.1e+00
1.6e+00
1.9e+00
—
1.8e+00
1.2e+00
1.1e+00
cases:7.03%
controls:2.39%
cases:5.84%
controls:1.29%
cases:2.72%
controls:0.43%
—
—
cases:1.95%
controls:0.31%
cases:4.35%
controls:1.34%
cases:6.81%
controls:2.39%
18
61
238
2493
15
33
242
2531
7
11
250
2553
—
5
8
252
2552
11
34
242
2499
16
56
219
2291
Physiotherapy
R4110 [2001310233]
1.1e+00
1.6e+00
—
—
—
1.6e+00
1.3e+00
cases:10.94%
controls:3.88%
cases:7.39%
controls:1.52%
—
—
—
—
—
—
cases:7.91%
controls:1.74%
cases:11.91%
controls:3.54%
28
99
228
2455
19
39
238
2525
—
—
—
20
44
233
2489
28
83
207
2264
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
1.1e+00
1.7e+00
—
—
—
1.5e+00
1.2e+00
cases:5.08%
controls:1.68%
cases:5.45%
controls:1.01%
—
—
—
—
—
—
cases:4.35%
controls:1.03%
cases:5.96%
controls:1.83%
13
43
243
2511
14
26
243
2538
—
—
—
11
26
242
2507
14
43
221
2304
Cells panel - Urine sediment
58434-2 [40761535]
1.2e+00
2.2e+00
—
—
—
1.6e+00
1.7e+00
cases:3.52%
controls:1.14%
cases:3.89%
controls:0.47%
—
—
—
—
—
—
cases:3.16%
controls:0.63%
cases:6.81%
controls:1.28%
9
29
247
2525
10
12
247
2552
—
—
—
8
16
245
2517
16
30
219
2317
methylprednisolone; oral, parenteral
H02AB04 [21602732]
1.9e+00
2.0e+00
—
—
—
1.5e+00
1.5e+00
cases:11.33%
controls:1.80%
cases:5.45%
controls:0.74%
—
—
—
—
—
—
cases:3.16%
controls:0.71%
cases:5.53%
controls:1.28%
29
46
227
2508
14
19
243
2545
—
—
—
8
18
245
2515
13
30
222
2317
Crohn disease, unspecified
K50.9 [45562490]
—
2.7e+00
—
—
—
—
2.8e+00
—
—
cases:2.72%
controls:0.20%
—
—
—
—
—
—
—
—
cases:3.40%
controls:0.21%
—
7
5
250
2559
—
—
—
—
8
5
227
2342
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
5.2e-01
1.1e+00
1.6e+00
—
2.0e+00
7.2e-01
7.1e-01
cases:7.81%
controls:4.82%
cases:7.00%
controls:2.54%
cases:3.11%
controls:0.62%
—
—
cases:2.72%
controls:0.39%
cases:7.91%
controls:4.03%
cases:21.70%
controls:11.97%
20
123
236
2431
18
65
239
2499
8
16
249
2548
—
7
10
250
2550
20
102
233
2431
51
281
184
2066
ciclesonide; nasal
R01AD13 [43534836]
1.3e+00
2.0e+00
—
—
—
1.7e+00
1.5e+00
cases:3.91%
controls:1.06%
cases:3.89%
controls:0.55%
—
—
—
—
—
—
cases:3.95%
controls:0.71%
cases:5.96%
controls:1.41%
10
27
246
2527
10
14
247
2550
—
—
—
10
18
243
2515
14
33
221
2314
ciclesonide; inhalant
R03BA08 [21603291]
1.3e+00
2.0e+00
—
—
—
1.7e+00
1.5e+00
cases:3.91%
controls:1.06%
cases:3.89%
controls:0.55%
—
—
—
—
—
—
cases:3.95%
controls:0.71%
cases:5.96%
controls:1.41%
10
27
246
2527
10
14
247
2550
—
—
—
10
18
243
2515
14
33
221
2314
Paranasal sinuses X-ray examination without contrast
DM1AA [2001301740]
2.2e+00
—
—
—
—
—
3.0e+00
cases:2.73%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:5.11%
controls:0.26%
7
8
249
2546
—
—
—
—
—
12
6
223
2341
General anesthesia, balanced
WX408 [2001310808]
8.4e-01
1.1e+00
—
—
—
2.6e+00
1.8e+00
cases:10.16%
controls:4.66%
cases:4.67%
controls:1.60%
—
—
—
—
—
—
cases:6.32%
controls:0.51%
cases:12.77%
controls:2.34%
26
119
230
2435
12
41
245
2523
—
—
—
16
13
237
2520
30
55
205
2292
One hour or less
ZXE00 [2001311394]
8.0e-01
1.3e+00
—
—
—
1.7e+00
1.4e+00
cases:14.84%
controls:7.28%
cases:7.39%
controls:2.03%
—
—
—
—
—
—
cases:6.72%
controls:1.34%
cases:14.89%
controls:4.22%
38
186
218
2368
19
52
238
2512
—
—
—
17
34
236
2499
35
99
200
2248
ebastine; oral
R06AX22 [21603521]
1.0e+00
1.4e+00
—
—
2.3e+00
1.4e+00
1.4e+00
cases:6.64%
controls:2.51%
cases:4.67%
controls:1.17%
—
—
—
—
cases:1.95%
controls:0.20%
cases:4.74%
controls:1.26%
cases:8.09%
controls:2.13%
17
64
239
2490
12
30
245
2534
—
—
5
5
252
2555
12
32
241
2501
19
50
216
2297
levocetirizine; oral
R06AE09 [21603498]
9.4e-01
1.4e+00
—
—
—
1.4e+00
1.4e+00
cases:6.64%
controls:2.70%
cases:5.06%
controls:1.29%
—
—
—
—
—
—
cases:5.53%
controls:1.42%
cases:8.94%
controls:2.39%
17
69
239
2485
13
33
244
2531
—
—
—
14
36
239
2497
21
56
214
2291
omeprazole; oral, parenteral
A02BC01 [21600096]
1.4e+00
1.3e+00
—
—
—
1.4e+00
1.1e+00
cases:12.89%
controls:3.68%
cases:6.23%
controls:1.76%
—
—
—
—
—
—
cases:5.93%
controls:1.54%
cases:9.36%
controls:3.41%
33
94
223
2460
16
45
241
2519
—
—
—
15
39
238
2494
22
80
213
2267
Physical Medicine And Rehabilitation
25 [38004468]
1.3e+00
1.4e+00
—
—
—
1.3e+00
1.1e+00
cases:18.36%
controls:5.64%
cases:9.34%
controls:2.46%
—
—
—
—
—
—
cases:7.51%
controls:2.09%
cases:18.30%
controls:7.20%
47
144
209
2410
24
63
233
2501
—
—
—
19
53
234
2480
43
169
192
2178
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
1.0e+00
1.5e+00
—
—
—
1.4e+00
1.2e+00
cases:15.63%
controls:6.34%
cases:9.34%
controls:2.22%
—
—
—
—
—
—
cases:7.91%
controls:2.05%
cases:16.60%
controls:5.88%
40
162
216
2392
24
57
233
2507
—
—
—
20
52
233
2481
39
138
196
2209
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
5.3e-01
8.9e-01
1.8e+00
—
1.5e+00
1.3e+00
1.1e+00
cases:10.16%
controls:6.23%
cases:8.56%
controls:3.71%
cases:3.50%
controls:0.62%
—
—
cases:3.11%
controls:0.74%
cases:11.46%
controls:3.32%
cases:22.55%
controls:8.78%
26
159
230
2395
22
95
235
2469
9
16
248
2548
—
8
19
249
2541
29
84
224
2449
53
206
182
2141
Allergy, unspecified
T78.4 [45580373]
2.0e+00
3.0e+00
—
—
—
—
—
cases:4.30%
controls:0.59%
cases:4.67%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
11
15
245
2539
12
6
245
2558
—
—
—
—
—
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
1.5e+00
1.6e+00
—
—
—
1.8e+00
1.7e+00
cases:6.64%
controls:1.49%
cases:3.11%
controls:0.66%
—
—
—
—
—
—
cases:2.77%
controls:0.47%
cases:8.94%
controls:1.75%
17
38
239
2516
8
17
249
2547
—
—
—
7
12
246
2521
21
41
214
2306
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
1.3e+00
1.8e+00
—
—
—
1.7e+00
1.6e+00
cases:3.91%
controls:1.14%
cases:3.11%
controls:0.55%
—
—
—
—
—
—
cases:3.16%
controls:0.59%
cases:9.36%
controls:2.09%
10
29
246
2525
8
14
249
2550
—
—
—
8
15
245
2518
22
49
213
2298
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
1.0e+00
1.6e+00
—
—
—
2.0e+00
1.4e+00
cases:3.91%
controls:1.45%
cases:4.28%
controls:0.86%
—
—
—
—
—
—
cases:5.93%
controls:0.87%
cases:9.36%
controls:2.43%
10
37
246
2517
11
22
246
2542
—
—
—
15
22
238
2511
22
57
213
2290
pantoprazole; oral, parenteral
A02BC02 [21600097]
7.6e-01
1.0e+00
1.4e+00
—
1.1e+00
9.9e-01
8.2e-01
cases:25.78%
controls:14.02%
cases:19.07%
controls:7.72%
cases:5.45%
controls:1.37%
—
—
cases:4.67%
controls:1.56%
cases:19.37%
controls:8.17%
cases:31.91%
controls:17.13%
66
358
190
2196
49
198
208
2366
14
35
243
2529
—
12
40
245
2520
49
207
204
2326
75
402
160
1945
salbutamol; inhalant
R03AC02 [21603256]
1.2e+00
1.5e+00
5.5e-01
—
1.3e+00
1.3e+00
1.0e+00
cases:39.45%
controls:16.13%
cases:26.46%
controls:7.68%
cases:2.33%
controls:1.37%
—
—
cases:4.28%
controls:1.25%
cases:23.32%
controls:7.82%
cases:37.45%
controls:17.43%
101
412
155
2142
68
197
189
2367
6
35
251
2529
—
11
32
246
2528
59
198
194
2335
88
409
147
1938
Hypothyroidism, unspecified
E03.9 [45537945]
1.5e+00
1.7e+00
—
1.0e+50
—
1.8e+00
5.6e-01
cases:6.64%
controls:1.57%
cases:3.11%
controls:0.59%
—
—
cases:3.11%
controls:0.00%
—
—
cases:3.95%
controls:0.67%
cases:4.68%
controls:2.73%
17
40
239
2514
8
15
249
2549
—
8
0
249
2564
—
10
17
243
2516
11
64
224
2283
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
1.8e+00
1.3e+00
—
—
—
1.7e+00
1.5e+00
cases:6.25%
controls:1.10%
cases:2.33%
controls:0.62%
—
—
—
—
—
—
cases:3.16%
controls:0.59%
cases:5.96%
controls:1.41%
16
28
240
2526
6
16
251
2548
—
—
—
8
15
245
2518
14
33
221
2314
duloxetine; oral
N06AX21 [21604749]
1.4e+00
2.1e+00
—
—
—
1.3e+00
1.5e+00
cases:4.69%
controls:1.25%
cases:3.11%
controls:0.39%
—
—
—
—
—
—
cases:1.98%
controls:0.55%
cases:7.66%
controls:1.79%
12
32
244
2522
8
10
249
2554
—
—
—
5
14
248
2519
18
42
217
2305
Case Management Agency
251B00000X [38004193]
4.3e-01
5.2e-01
7.0e-01
3.1e+00
6.3e-01
3.3e-01
1.8e-01
cases:69.14%
controls:59.20%
cases:67.70%
controls:55.46%
cases:36.19%
controls:21.92%
cases:24.51%
controls:1.48%
cases:33.85%
controls:21.45%
cases:66.80%
controls:59.14%
cases:85.96%
controls:83.60%
177
1512
79
1042
174
1422
83
1142
93
562
164
2002
63
38
194
2526
87
549
170
2011
169
1498
84
1035
202
1962
33
385
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.4e-01
7.4e-01
1.3e+00
—
1.3e+00
8.2e-01
7.2e-01
cases:19.53%
controls:17.46%
cases:25.68%
controls:14.16%
cases:10.51%
controls:3.08%
—
—
cases:8.95%
controls:2.66%
cases:28.46%
controls:14.92%
cases:50.64%
controls:33.23%
50
446
206
2108
66
363
191
2201
27
79
230
2485
—
23
68
234
2492
72
378
181
2155
119
780
116
1567
Endocrinology
46 [38004485]
8.7e-01
1.1e+00
1.3e+00
—
1.6e+00
1.1e+00
1.0e+00
cases:7.42%
controls:3.25%
cases:7.00%
controls:2.34%
cases:2.33%
controls:0.62%
—
—
cases:3.11%
controls:0.63%
cases:7.51%
controls:2.68%
cases:12.34%
controls:4.86%
19
83
237
2471
18
60
239
2504
6
16
251
2548
—
8
16
249
2544
19
68
234
2465
29
114
206
2233
Other and unspecified abdominal pain
R10.4 [45568113]
1.1e+00
1.3e+00
—
—
—
1.3e+00
1.2e+00
cases:16.02%
controls:5.79%
cases:6.61%
controls:1.87%
—
—
—
—
—
—
cases:5.53%
controls:1.62%
cases:19.15%
controls:6.95%
41
148
215
2406
17
48
240
2516
—
—
—
14
41
239
2492
45
163
190
2184
Asthma
J45 [45596282]
1.6e+00
2.2e+00
—
—
—
1.5e+00
1.1e+00
cases:9.38%
controls:2.08%
cases:3.11%
controls:0.35%
—
—
—
—
—
—
cases:2.77%
controls:0.63%
cases:6.38%
controls:2.30%
24
53
232
2501
8
9
249
2555
—
—
—
7
16
246
2517
15
54
220
2293
Leukocytes [#/volume] in Urine
30405-5 [3018095]
7.0e-01
1.0e+00
—
—
1.9e+00
9.5e-01
1.0e+00
cases:7.42%
controls:3.84%
cases:6.61%
controls:2.54%
—
—
—
—
cases:2.72%
controls:0.43%
cases:7.51%
controls:3.04%
cases:19.57%
controls:7.97%
19
98
237
2456
17
65
240
2499
—
—
7
11
250
2549
19
77
234
2456
46
187
189
2160
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
2.3e+00
2.5e+00
—
—
—
—
—
cases:2.34%
controls:0.23%
cases:2.33%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
6
6
250
2548
6
5
251
2559
—
—
—
—
—
Pediatric Medicine
37 [38004477]
3.7e-01
8.6e-01
1.0e+00
—
1.6e+00
1.2e+00
1.1e+00
cases:9.38%
controls:6.66%
cases:8.56%
controls:3.82%
cases:2.33%
controls:0.86%
—
—
cases:4.28%
controls:0.86%
cases:9.49%
controls:3.08%
cases:11.06%
controls:3.96%
24
170
232
2384
22
98
235
2466
6
22
251
2542
—
11
22
246
2538
24
78
229
2455
26
93
209
2254
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.1e+00
1.3e+00
—
—
1.6e+00
1.3e+00
1.0e+00
cases:9.38%
controls:3.29%
cases:5.06%
controls:1.40%
—
—
—
—
cases:1.95%
controls:0.39%
cases:6.32%
controls:1.82%
cases:10.64%
controls:4.05%
24
84
232
2470
13
36
244
2528
—
—
5
10
252
2550
16
46
237
2487
25
95
210
2252
calcium (different salts in combination); oral
A12AA20 [21600872]
1.1e+00
1.3e+00
8.9e-01
—
9.6e-01
9.9e-01
1.3e+00
cases:16.41%
controls:6.07%
cases:15.56%
controls:4.76%
cases:2.33%
controls:0.98%
—
—
cases:3.11%
controls:1.21%
cases:12.65%
controls:5.09%
cases:22.13%
controls:7.03%
42
155
214
2399
40
122
217
2442
6
25
251
2539
—
8
31
249
2529
32
129
221
2404
52
165
183
2182
Dyspnoea
R06.0 [45558449]
1.5e+00
1.7e+00
—
—
—
1.4e+00
1.4e+00
cases:11.72%
controls:2.78%
cases:3.89%
controls:0.70%
—
—
—
—
—
—
cases:2.77%
controls:0.67%
cases:10.64%
controls:2.77%
30
71
226
2483
10
18
247
2546
—
—
—
7
17
246
2516
25
65
210
2282
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
—
2.9e+00
—
—
—
1.8e+00
1.5e+00
—
—
cases:3.50%
controls:0.20%
—
—
—
—
—
—
cases:2.77%
controls:0.47%
cases:3.40%
controls:0.81%
—
9
5
248
2559
—
—
—
7
12
246
2521
8
19
227
2328
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
2.5e+00
—
—
—
—
2.1e+00
2.2e+00
cases:3.13%
controls:0.27%
—
—
—
—
—
—
—
—
cases:1.98%
controls:0.24%
cases:6.38%
controls:0.72%
8
7
248
2547
—
—
—
—
5
6
248
2527
15
17
220
2330
Abdominal ultrasound examination
JN3AE [2001305555]
1.2e+00
1.2e+00
—
—
—
1.8e+00
1.7e+00
cases:5.86%
controls:1.88%
cases:2.72%
controls:0.82%
—
—
—
—
—
—
cases:3.56%
controls:0.63%
cases:9.36%
controls:1.79%
15
48
241
2506
7
21
250
2543
—
—
—
9
16
244
2517
22
42
213
2305
Chronic maxillary sinusitis
J32.0 [45586667]
2.2e+00
—
—
—
1.0e+50
—
2.5e+00
cases:7.03%
controls:0.86%
—
—
—
—
—
—
cases:2.72%
controls:0.00%
—
—
cases:7.66%
controls:0.68%
18
22
238
2532
—
—
—
7
0
250
2560
—
18
16
217
2331
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.4e-01
5.7e-01
1.3e+00
—
1.3e+00
7.5e-01
6.4e-01
cases:27.34%
controls:22.87%
cases:29.96%
controls:19.42%
cases:14.79%
controls:4.41%
—
—
cases:13.23%
controls:3.83%
cases:35.18%
controls:20.41%
cases:59.15%
controls:43.20%
70
584
186
1970
77
498
180
2066
38
113
219
2451
—
34
98
223
2462
89
517
164
2016
139
1014
96
1333
combinations of corticosteroids
D07AB30 [21602118]
1.1e+00
1.2e+00
—
—
—
1.4e+00
8.9e-01
cases:23.83%
controls:9.40%
cases:10.12%
controls:3.43%
—
—
—
—
—
—
cases:13.83%
controls:3.63%
cases:21.70%
controls:10.18%
61
240
195
2314
26
88
231
2476
—
—
—
35
92
218
2441
51
239
184
2108
combinations of corticosteroids
D07XB30 [21602188]
1.1e+00
1.2e+00
—
—
—
1.4e+00
8.9e-01
cases:23.83%
controls:9.40%
cases:10.12%
controls:3.43%
—
—
—
—
—
—
cases:13.83%
controls:3.63%
cases:21.70%
controls:10.18%
61
240
195
2314
26
88
231
2476
—
—
—
35
92
218
2441
51
239
184
2108
methotrexate
L01BA01 [21601423]
1.8e+00
1.6e+00
—
—
1.4e+00
1.2e+00
1.2e+00
cases:7.03%
controls:1.29%
cases:5.84%
controls:1.25%
—
—
—
—
cases:1.95%
controls:0.47%
cases:4.35%
controls:1.30%
cases:5.53%
controls:1.70%
18
33
238
2521
15
32
242
2532
—
—
5
12
252
2548
11
33
242
2500
13
40
222
2307
methotrexate; oral, parenteral
L04AX03 [21603929]
1.8e+00
1.6e+00
—
—
1.4e+00
1.2e+00
1.2e+00
cases:7.03%
controls:1.29%
cases:5.84%
controls:1.25%
—
—
—
—
cases:1.95%
controls:0.47%
cases:4.35%
controls:1.30%
cases:5.53%
controls:1.70%
18
33
238
2521
15
32
242
2532
—
—
5
12
252
2548
11
33
242
2500
13
40
222
2307
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
7.5e-01
8.7e-01
—
—
2.1e+00
1.2e+00
1.3e+00
cases:5.86%
controls:2.86%
cases:5.06%
controls:2.18%
—
—
—
—
cases:2.72%
controls:0.35%
cases:7.11%
controls:2.21%
cases:17.02%
controls:5.54%
15
73
241
2481
13
56
244
2508
—
—
7
9
250
2551
18
56
235
2477
40
130
195
2217
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.5e+00
1.2e+00
—
—
—
1.6e+00
1.3e+00
cases:11.72%
controls:2.74%
cases:4.67%
controls:1.48%
—
—
—
—
—
—
cases:4.74%
controls:0.95%
cases:12.77%
controls:3.71%
30
70
226
2484
12
38
245
2526
—
—
—
12
24
241
2509
30
87
205
2260
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
7.3e-01
7.9e-01
6.3e-01
-1.0e+50
1.1e+00
1.0e+00
8.7e-01
cases:47.27%
controls:30.07%
cases:28.79%
controls:15.44%
cases:3.89%
controls:2.11%
cases:0.00%
controls:0.23%
cases:6.61%
controls:2.34%
cases:32.81%
controls:15.04%
cases:57.87%
controls:36.43%
121
768
135
1786
74
396
183
2168
10
54
247
2510
0
6
257
2558
17
60
240
2500
83
381
170
2152
136
855
99
1492
cromoglicic acid
S01GX01 [21605085]
1.3e+00
1.7e+00
—
—
-1.0e+50
7.1e-01
1.4e+00
cases:12.50%
controls:3.72%
cases:7.00%
controls:1.33%
—
—
—
—
cases:0.00%
controls:0.27%
cases:3.56%
controls:1.78%
cases:12.77%
controls:3.62%
32
95
224
2459
18
34
239
2530
—
—
0
7
257
2553
9
45
244
2488
30
85
205
2262
Bacteria [Presence] in Urine
87829-8 [36304419]
6.6e-01
7.5e-01
—
—
2.0e+00
1.1e+00
1.2e+00
cases:5.47%
controls:2.90%
cases:4.28%
controls:2.07%
—
—
—
—
cases:2.33%
controls:0.31%
cases:5.93%
controls:2.01%
cases:16.60%
controls:5.45%
14
74
242
2480
11
53
246
2511
—
—
6
8
251
2552
15
51
238
2482
39
128
196
2219
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
—
2.3e+00
—
—
1.0e+50
2.1e+00
2.3e+00
—
—
cases:1.95%
controls:0.20%
—
—
—
—
cases:1.95%
controls:0.00%
cases:3.16%
controls:0.39%
cases:5.53%
controls:0.60%
—
5
5
252
2559
—
—
5
0
252
2560
8
10
245
2523
13
14
222
2333
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.1e+00
1.1e+00
—
—
—
1.9e+00
1.3e+00
cases:8.98%
controls:3.25%
cases:4.67%
controls:1.68%
—
—
—
—
—
—
cases:7.91%
controls:1.26%
cases:16.17%
controls:4.86%
23
83
233
2471
12
43
245
2521
—
—
—
20
32
233
2501
38
114
197
2233
hydrocortisone
S02BA01 [21605166]
9.0e-01
1.1e+00
—
—
—
1.2e+00
1.1e+00
cases:13.67%
controls:6.03%
cases:6.61%
controls:2.26%
—
—
—
—
—
—
cases:6.72%
controls:2.13%
cases:16.60%
controls:6.31%
35
154
221
2400
17
58
240
2506
—
—
—
17
54
236
2479
39
148
196
2199
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
7.1e-01
1.5e+00
2.1e+00
—
—
1.7e+00
1.1e+00
cases:7.03%
controls:3.60%
cases:7.39%
controls:1.72%
cases:1.95%
controls:0.23%
—
—
—
—
cases:6.32%
controls:1.26%
cases:19.15%
controls:7.20%
18
92
238
2462
19
44
238
2520
5
6
252
2558
—
—
16
32
237
2501
45
169
190
2178
Other specified special examinations
Z01.8 [45581003]
1.3e+00
1.3e+00
—
—
—
1.7e+00
1.2e+00
cases:8.98%
controls:2.51%
cases:3.50%
controls:0.94%
—
—
—
—
—
—
cases:4.74%
controls:0.91%
cases:11.06%
controls:3.45%
23
64
233
2490
9
24
248
2540
—
—
—
12
23
241
2510
26
81
209
2266
More than one and less than three hours
ZXE10 [2001311401]
9.1e-01
8.1e-01
—
—
—
1.7e+00
1.7e+00
cases:12.89%
controls:5.60%
cases:4.28%
controls:1.95%
—
—
—
—
—
—
cases:6.32%
controls:1.22%
cases:14.04%
controls:3.03%
33
143
223
2411
11
50
246
2514
—
—
—
16
31
237
2502
33
71
202
2276
gabapentin; oral
N02BF01 [955005]
1.6e+00
1.5e+00
1.4e+00
—
1.9e+00
1.2e+00
1.1e+00
cases:8.59%
controls:1.92%
cases:5.84%
controls:1.33%
cases:1.95%
controls:0.47%
—
—
cases:2.33%
controls:0.35%
cases:4.74%
controls:1.46%
cases:8.51%
controls:2.98%
22
49
234
2505
15
34
242
2530
5
12
252
2552
—
6
9
251
2551
12
37
241
2496
20
70
215
2277
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.3e-01
4.7e-01
1.3e+00
—
1.5e+00
7.8e-01
6.7e-01
cases:25.78%
controls:21.57%
cases:25.29%
controls:17.47%
cases:10.89%
controls:3.28%
—
—
cases:11.28%
controls:2.85%
cases:31.62%
controls:17.45%
cases:54.47%
controls:37.92%
66
551
190
2003
65
448
192
2116
28
84
229
2480
—
29
73
228
2487
80
442
173
2091
128
890
107
1457
Bacterial infection, unspecified
A49.9 [45590816]
2.0e+00
—
—
—
—
2.2e+00
1.5e+00
cases:3.13%
controls:0.43%
—
—
—
—
—
—
—
—
cases:2.37%
controls:0.28%
cases:3.40%
controls:0.81%
8
11
248
2543
—
—
—
—
6
7
247
2526
8
19
227
2328
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
5.0e-01
9.1e-01
1.6e+00
—
1.4e+00
8.9e-01
7.2e-01
cases:17.58%
controls:11.47%
cases:14.40%
controls:6.36%
cases:4.28%
controls:0.86%
—
—
cases:3.50%
controls:0.86%
cases:13.44%
controls:6.00%
cases:31.91%
controls:18.53%
45
293
211
2261
37
163
220
2401
11
22
246
2542
—
9
22
248
2538
34
152
219
2381
75
435
160
1912
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.3e-01
4.6e-01
1.3e+00
—
1.4e+00
7.5e-01
6.8e-01
cases:25.78%
controls:21.57%
cases:24.90%
controls:17.24%
cases:10.89%
controls:3.32%
—
—
cases:10.89%
controls:2.81%
cases:30.83%
controls:17.33%
cases:54.47%
controls:37.84%
66
551
190
2003
64
442
193
2122
28
85
229
2479
—
28
72
229
2488
78
439
175
2094
128
888
107
1459
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
1.3e+00
1.3e+00
2.1e+00
—
—
1.6e+00
6.6e-01
cases:11.33%
controls:3.33%
cases:7.39%
controls:2.18%
cases:1.95%
controls:0.23%
—
—
—
—
cases:6.72%
controls:1.50%
cases:14.47%
controls:8.01%
29
85
227
2469
19
56
238
2508
5
6
252
2558
—
—
17
38
236
2495
34
188
201
2159
mometasone; nasal
R01AD09 [21605051]
9.8e-01
1.0e+00
—
—
—
1.1e+00
1.0e+00
cases:25.00%
controls:11.08%
cases:10.51%
controls:4.02%
—
—
—
—
—
—
cases:10.67%
controls:3.79%
cases:22.98%
controls:9.84%
64
283
192
2271
27
103
230
2461
—
—
—
27
96
226
2437
54
231
181
2116
hydrocortisone aceponate
D07AC16 [21602135]
7.8e-01
1.1e+00
—
—
—
1.2e+00
1.1e+00
cases:14.45%
controls:7.20%
cases:7.39%
controls:2.54%
—
—
—
—
—
—
cases:7.51%
controls:2.45%
cases:18.72%
controls:7.41%
37
184
219
2370
19
65
238
2499
—
—
—
19
62
234
2471
44
174
191
2173
hydrocortisone butyrate
D07AB02 [21602106]
7.8e-01
1.1e+00
—
—
—
1.2e+00
1.1e+00
cases:14.45%
controls:7.20%
cases:7.39%
controls:2.54%
—
—
—
—
—
—
cases:7.51%
controls:2.45%
cases:18.72%
controls:7.41%
37
184
219
2370
19
65
238
2499
—
—
—
19
62
234
2471
44
174
191
2173
hydrocortisone buteprate
D07AB11 [21602115]
7.8e-01
1.1e+00
—
—
—
1.2e+00
1.1e+00
cases:14.45%
controls:7.20%
cases:7.39%
controls:2.54%
—
—
—
—
—
—
cases:7.51%
controls:2.45%
cases:18.72%
controls:7.41%
37
184
219
2370
19
65
238
2499
—
—
—
19
62
234
2471
44
174
191
2173
hydrocortisone
D07AA02 [21602102]
7.8e-01
1.1e+00
—
—
—
1.2e+00
1.1e+00
cases:14.45%
controls:7.20%
cases:7.39%
controls:2.54%
—
—
—
—
—
—
cases:7.51%
controls:2.45%
cases:18.72%
controls:7.41%
37
184
219
2370
19
65
238
2499
—
—
—
19
62
234
2471
44
174
191
2173
hydrocortisone
C05AA01 [21601608]
7.7e-01
1.1e+00
—
—
—
1.2e+00
1.1e+00
cases:14.45%
controls:7.28%
cases:7.39%
controls:2.54%
—
—
—
—
—
—
cases:7.51%
controls:2.45%
cases:18.72%
controls:7.41%
37
186
219
2368
19
65
238
2499
—
—
—
19
62
234
2471
44
174
191
2173
hydrocortisone
A07EA02 [21600654]
7.7e-01
1.1e+00
—
—
—
1.2e+00
1.1e+00
cases:14.45%
controls:7.28%
cases:7.39%
controls:2.54%
—
—
—
—
—
—
cases:7.51%
controls:2.45%
cases:18.72%
controls:7.41%
37
186
219
2368
19
65
238
2499
—
—
—
19
62
234
2471
44
174
191
2173
Spirometry
127783003 [4133840]
1.6e+00
1.6e+00
—
—
—
2.5e+00
—
cases:3.52%
controls:0.70%
cases:1.95%
controls:0.39%
—
—
—
—
—
—
cases:2.77%
controls:0.24%
—
—
9
18
247
2536
5
10
252
2554
—
—
—
7
6
246
2527
—
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
—
2.3e+00
—
—
—
—
1.8e+00
—
—
cases:2.33%
controls:0.23%
—
—
—
—
—
—
—
—
cases:2.98%
controls:0.51%
—
6
6
251
2558
—
—
—
—
7
12
228
2335
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
—
—
—
—
—
2.0e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:3.56%
controls:0.51%
cases:10.21%
controls:1.32%
—
—
—
—
—
9
13
244
2520
24
31
211
2316
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.8e-01
6.4e-01
1.3e+00
—
9.4e-01
6.9e-01
5.6e-01
cases:25.00%
controls:21.85%
cases:28.40%
controls:17.28%
cases:11.28%
controls:3.43%
—
—
cases:7.78%
controls:3.20%
cases:31.23%
controls:18.56%
cases:56.17%
controls:42.27%
64
558
192
1996
73
443
184
2121
29
88
228
2476
—
20
82
237
2478
79
470
174
2063
132
992
103
1355
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
2.0e+00
2.3e+00
—
—
—
—
2.1e+00
cases:2.73%
controls:0.39%
cases:1.95%
controls:0.20%
—
—
—
—
—
—
—
—
cases:3.83%
controls:0.47%
7
10
249
2544
5
5
252
2559
—
—
—
—
9
11
226
2336
lactulose; oral
A06AD11 [21600571]
1.4e+00
1.5e+00
—
—
—
2.5e+00
1.6e+00
cases:3.52%
controls:0.86%
cases:1.95%
controls:0.43%
—
—
—
—
—
—
cases:3.56%
controls:0.32%
cases:4.68%
controls:0.94%
9
22
247
2532
5
11
252
2553
—
—
—
9
8
244
2525
11
22
224
2325
fluticasone; inhalant
R03BA05 [21603288]
1.0e+00
1.6e+00
—
—
—
1.4e+00
7.3e-01
cases:11.72%
controls:4.58%
cases:9.34%
controls:1.95%
—
—
—
—
—
—
cases:7.11%
controls:1.89%
cases:7.66%
controls:3.83%
30
117
226
2437
24
50
233
2514
—
—
—
18
48
235
2485
18
90
217
2257
Acute tubulo-interstitial nephritis
N10 [45543856]
1.1e+00
2.3e+00
—
—
—
—
1.7e+00
cases:2.73%
controls:0.90%
cases:3.11%
controls:0.31%
—
—
—
—
—
—
—
—
cases:5.11%
controls:0.98%
7
23
249
2531
8
8
249
2556
—
—
—
—
12
23
223
2324
sulfadiazine and trimethoprim
J01EE02 [21602962]
1.0e+00
1.7e+00
—
—
—
1.4e+00
1.2e+00
cases:9.77%
controls:3.68%
cases:5.06%
controls:0.94%
—
—
—
—
—
—
cases:3.56%
controls:0.91%
cases:6.81%
controls:2.09%
25
94
231
2460
13
24
244
2540
—
—
—
9
23
244
2510
16
49
219
2298
nystatin; oral
A07AA02 [21600604]
1.6e+00
—
—
—
—
2.3e+00
1.6e+00
cases:2.73%
controls:0.55%
—
—
—
—
—
—
—
—
cases:2.77%
controls:0.28%
cases:3.40%
controls:0.68%
7
14
249
2540
—
—
—
—
7
7
246
2526
8
16
227
2331
dexamethasone and antiinfectives
S02CA06 [21605178]
1.6e+00
—
—
—
—
2.3e+00
1.5e+00
cases:3.13%
controls:0.63%
—
—
—
—
—
—
—
—
cases:2.37%
controls:0.24%
cases:3.40%
controls:0.77%
8
16
248
2538
—
—
—
—
6
6
247
2527
8
18
227
2329
Acute maxillary sinusitis
J01.0 [45601112]
1.8e+00
1.4e+00
—
—
—
5.2e-01
7.9e-01
cases:14.84%
controls:2.94%
cases:5.84%
controls:1.56%
—
—
—
—
—
—
cases:2.37%
controls:1.42%
cases:11.49%
controls:5.54%
38
75
218
2479
15
40
242
2524
—
—
—
6
36
247
2497
27
130
208
2217
Malaise and fatigue
R53 [45553741]
1.2e+00
1.5e+00
—
—
—
—
1.2e+00
cases:6.64%
controls:2.11%
cases:5.06%
controls:1.13%
—
—
—
—
—
—
—
—
cases:12.77%
controls:4.30%
17
54
239
2500
13
29
244
2535
—
—
—
—
30
101
205
2246
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
1.1e+00
1.6e+00
—
—
—
2.5e+00
1.4e+00
cases:2.34%
controls:0.82%
cases:1.95%
controls:0.39%
—
—
—
—
—
—
cases:2.77%
controls:0.24%
cases:4.26%
controls:1.07%
6
21
250
2533
5
10
252
2554
—
—
—
7
6
246
2527
10
25
225
2322
Carboxyhemoglobin/Hemoglobin.total in Venous blood
2032-1 [3010517]
—
—
—
—
—
2.5e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:2.77%
controls:0.24%
cases:4.26%
controls:1.07%
—
—
—
—
—
7
6
246
2527
10
25
225
2322
Methemoglobin/Hemoglobin.total in Venous blood
2617-9 [3024889]
—
—
—
—
—
2.5e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:2.77%
controls:0.24%
cases:4.26%
controls:1.07%
—
—
—
—
—
7
6
246
2527
10
25
225
2322
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.3e+00
2.2e+00
—
—
—
—
1.7e+00
cases:2.34%
controls:0.63%
cases:4.28%
controls:0.51%
—
—
—
—
—
—
—
—
cases:5.11%
controls:0.98%
6
16
250
2538
11
13
246
2551
—
—
—
—
12
23
223
2324
pH of Arterial blood
2744-1 [3019977]
1.3e+00
2.2e+00
—
—
—
—
1.7e+00
cases:2.34%
controls:0.63%
cases:4.28%
controls:0.51%
—
—
—
—
—
—
—
—
cases:5.11%
controls:0.98%
6
16
250
2538
11
13
246
2551
—
—
—
—
12
23
223
2324
Laboratory test
15220000 [4034850]
1.0e+00
1.4e+00
—
—
—
1.5e+00
7.2e-01
cases:5.86%
controls:2.19%
cases:3.89%
controls:1.01%
—
—
—
—
—
—
cases:4.74%
controls:1.14%
cases:7.66%
controls:3.88%
15
56
241
2498
10
26
247
2538
—
—
—
12
29
241
2504
18
91
217
2256
Bilateral
ZXA10 [2001311348]
7.8e-02
1.3e+00
—
—
—
2.5e+00
1.3e+00
cases:3.13%
controls:2.90%
cases:2.33%
controls:0.66%
—
—
—
—
—
—
cases:4.74%
controls:0.39%
cases:5.53%
controls:1.53%
8
74
248
2480
6
17
251
2547
—
—
—
12
10
241
2523
13
36
222
2311
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
2.2e+00
1.7e+00
—
—
—
—
1.6e+00
cases:5.08%
controls:0.59%
cases:2.33%
controls:0.43%
—
—
—
—
—
—
—
—
cases:4.26%
controls:0.85%
13
15
243
2539
6
11
251
2553
—
—
—
—
10
20
225
2327
Bacteria identified in Isolate by Culture
43409-2 [3042936]
7.5e-01
2.2e+00
—
—
—
1.5e+00
1.7e+00
cases:3.91%
controls:1.88%
cases:4.28%
controls:0.51%
—
—
—
—
—
—
cases:2.37%
controls:0.55%
cases:7.66%
controls:1.53%
10
48
246
2506
11
13
246
2551
—
—
—
6
14
247
2519
18
36
217
2311
Oxygen saturation in Arterial blood
2708-6 [3016502]
1.4e+00
2.3e+00
—
—
—
—
1.5e+00
cases:1.95%
controls:0.47%
cases:3.89%
controls:0.39%
—
—
—
—
—
—
—
—
cases:4.26%
controls:0.98%
5
12
251
2542
10
10
247
2554
—
—
—
—
10
23
225
2324
Dorsalgia, unspecified
M54.9 [45538791]
1.7e+00
2.1e+00
—
—
—
—
5.5e-01
cases:4.30%
controls:0.78%
cases:2.72%
controls:0.35%
—
—
—
—
—
—
—
—
cases:2.55%
controls:1.49%
11
20
245
2534
7
9
250
2555
—
—
—
—
6
35
229
2312
Bacterial pneumonia, unspecified
J15.9 [45557621]
1.7e+00
—
—
—
—
—
2.1e+00
cases:3.13%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:3.40%
controls:0.43%
8
15
248
2539
—
—
—
—
—
8
10
227
2337
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
1.3e+00
1.6e+00
—
—
—
8.9e-01
9.0e-01
cases:26.56%
controls:9.12%
cases:12.06%
controls:2.65%
—
—
—
—
—
—
cases:6.32%
controls:2.68%
cases:19.15%
controls:8.82%
68
233
188
2321
31
68
226
2496
—
—
—
16
68
237
2465
45
207
190
2140
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
1.3e+00
2.2e+00
—
—
—
—
1.6e+00
cases:2.34%
controls:0.63%
cases:4.28%
controls:0.51%
—
—
—
—
—
—
—
—
cases:4.68%
controls:0.98%
6
16
250
2538
11
13
246
2551
—
—
—
—
11
23
224
2324
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
1.3e+00
2.2e+00
—
—
—
—
1.6e+00
cases:2.34%
controls:0.63%
cases:4.28%
controls:0.51%
—
—
—
—
—
—
—
—
cases:4.68%
controls:0.98%
6
16
250
2538
11
13
246
2551
—
—
—
—
11
23
224
2324
General Surgery
2 [38004447]
7.8e-01
8.7e-01
1.4e+00
—
1.3e+00
1.2e+00
8.6e-01
cases:25.78%
controls:13.74%
cases:10.12%
controls:4.49%
cases:1.95%
controls:0.47%
—
—
cases:1.95%
controls:0.55%
cases:11.86%
controls:3.87%
cases:20.85%
controls:10.06%
66
351
190
2203
26
115
231
2449
5
12
252
2552
—
5
14
252
2546
30
98
223
2435
49
236
186
2111
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
1.6e+00
2.2e+00
—
—
—
—
1.5e+00
cases:2.73%
controls:0.55%
cases:3.11%
controls:0.35%
—
—
—
—
—
—
—
—
cases:5.53%
controls:1.28%
7
14
249
2540
8
9
249
2555
—
—
—
—
13
30
222
2317
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
8.7e-01
1.6e+00
—
—
—
2.3e+00
1.4e+00
cases:4.30%
controls:1.84%
cases:2.33%
controls:0.47%
—
—
—
—
—
—
cases:3.16%
controls:0.32%
cases:4.68%
controls:1.24%
11
47
245
2507
6
12
251
2552
—
—
—
8
8
245
2525
11
29
224
2318
fluticasone furoate
R03BA09 [45893496]
9.4e-01
1.6e+00
—
—
—
1.1e+00
6.3e-01
cases:10.16%
controls:4.23%
cases:7.78%
controls:1.68%
—
—
—
—
—
—
cases:5.14%
controls:1.70%
cases:6.38%
controls:3.49%
26
108
230
2446
20
43
237
2521
—
—
—
13
43
240
2490
15
82
220
2265
bisoprolol; oral
C07AB07 [21601689]
5.4e-01
8.0e-01
8.3e-01
—
1.0e+00
9.8e-01
8.6e-01
cases:14.84%
controls:9.20%
cases:16.34%
controls:8.07%
cases:5.06%
controls:2.26%
—
—
cases:5.45%
controls:1.99%
cases:19.76%
controls:8.49%
cases:23.83%
controls:11.67%
38
235
218
2319
42
207
215
2357
13
58
244
2506
—
14
51
243
2509
50
215
203
2318
56
274
179
2073
Emergency Room and Inpatient Visit
ERIP [262]
4.4e-01
1.5e+00
—
—
—
1.3e+00
8.8e-01
cases:4.30%
controls:2.82%
cases:5.45%
controls:1.33%
—
—
—
—
—
—
cases:5.93%
controls:1.66%
cases:11.49%
controls:5.11%
11
72
245
2482
14
34
243
2530
—
—
—
15
42
238
2491
27
120
208
2227
fluticasone; nasal
R01AD08 [21605050]
9.5e-01
9.6e-01
1.3e+00
—
1.9e+00
9.1e-01
8.0e-01
cases:20.70%
controls:9.16%
cases:10.51%
controls:4.29%
cases:1.95%
controls:0.55%
—
—
cases:2.33%
controls:0.35%
cases:10.28%
controls:4.42%
cases:22.55%
controls:11.55%
53
234
203
2320
27
110
230
2454
5
14
252
2550
—
6
9
251
2551
26
112
227
2421
53
271
182
2076
fluticasone furoate; nasal
R01AD12 [21605053]
9.5e-01
9.6e-01
1.3e+00
—
1.9e+00
9.1e-01
8.0e-01
cases:20.70%
controls:9.16%
cases:10.51%
controls:4.29%
cases:1.95%
controls:0.55%
—
—
cases:2.33%
controls:0.35%
cases:10.28%
controls:4.42%
cases:22.55%
controls:11.55%
53
234
203
2320
27
110
230
2454
5
14
252
2550
—
6
9
251
2551
26
112
227
2421
53
271
182
2076
Bacteria identified in Urine by Culture
630-4 [3026008]
6.9e-01
1.6e+00
—
—
—
1.2e+00
8.8e-01
cases:6.25%
controls:3.25%
cases:6.23%
controls:1.37%
—
—
—
—
—
—
cases:5.14%
controls:1.66%
cases:12.34%
controls:5.50%
16
83
240
2471
16
35
241
2529
—
—
—
13
42
240
2491
29
129
206
2218
General Practice Dentistry
1223G0001X [38003675]
—
—
—
—
—
1.9e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:2.77%
controls:0.43%
cases:5.11%
controls:0.94%
—
—
—
—
—
7
11
246
2522
12
22
223
2325
Oral Surgery
19 [38004464]
1.5e+00
2.0e+00
—
—
—
—
1.6e+00
cases:3.13%
controls:0.70%
cases:2.72%
controls:0.39%
—
—
—
—
—
—
—
—
cases:4.26%
controls:0.85%
8
18
248
2536
7
10
250
2554
—
—
—
—
10
20
225
2327
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
5.3e-01
1.1e+00
2.5e+00
—
—
1.1e+00
1.1e+00
cases:4.69%
controls:2.82%
cases:4.67%
controls:1.68%
cases:2.33%
controls:0.20%
—
—
—
—
cases:4.74%
controls:1.62%
cases:12.77%
controls:4.73%
12
72
244
2482
12
43
245
2521
6
5
251
2559
—
—
12
41
241
2492
30
111
205
2236
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
5.7e-02
5.4e-01
1.2e+00
—
1.2e+00
5.7e-01
4.1e-01
cases:21.88%
controls:20.91%
cases:25.29%
controls:16.50%
cases:11.67%
controls:3.71%
—
—
cases:10.12%
controls:3.16%
cases:27.27%
controls:17.53%
cases:48.51%
controls:38.56%
56
534
200
2020
65
423
192
2141
30
95
227
2469
—
26
81
231
2479
69
444
184
2089
114
905
121
1442
INR in Blood by Coagulation assay
34714-6 [3032080]
5.2e-01
1.2e+00
1.2e+00
—
7.7e-01
1.3e+00
1.0e+00
cases:8.98%
controls:5.56%
cases:10.51%
controls:3.39%
cases:2.72%
controls:0.82%
—
—
cases:2.33%
controls:1.09%
cases:11.07%
controls:3.24%
cases:20.00%
controls:8.05%
23
142
233
2412
27
87
230
2477
7
21
250
2543
—
6
28
251
2532
28
82
225
2451
47
189
188
2158
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
4.4e-01
8.3e-01
1.5e+00
—
7.8e-01
1.1e+00
9.4e-01
cases:9.77%
controls:6.54%
cases:8.17%
controls:3.74%
cases:3.50%
controls:0.78%
—
—
cases:1.95%
controls:0.90%
cases:10.28%
controls:3.71%
cases:23.40%
controls:10.65%
25
167
231
2387
21
96
236
2468
9
20
248
2544
—
5
23
252
2537
26
94
227
2439
55
250
180
2097
Osmolality of Urine
2695-5 [3026782]
9.9e-01
1.2e+00
2.0e+00
—
—
7.6e-01
1.3e+00
cases:6.25%
controls:2.43%
cases:5.45%
controls:1.68%
cases:1.95%
controls:0.27%
—
—
—
—
cases:3.16%
controls:1.50%
cases:12.34%
controls:3.54%
16
62
240
2492
14
43
243
2521
5
7
252
2557
—
—
8
38
245
2495
29
83
206
2264
cefalexin; oral
J01DB01 [21602870]
9.5e-01
1.1e+00
9.6e-01
—
7.4e-01
8.2e-01
6.5e-01
cases:52.73%
controls:30.23%
cases:22.57%
controls:8.81%
cases:3.11%
controls:1.21%
—
—
cases:2.33%
controls:1.13%
cases:18.97%
controls:9.32%
cases:41.28%
controls:26.93%
135
772
121
1782
58
226
199
2338
8
31
249
2533
—
6
29
251
2531
48
236
205
2297
97
632
138
1715
antibiotics in combination with other drugs
S01AA20 [21603571]
9.9e-01
1.2e+00
—
—
—
1.3e+00
6.9e-01
cases:12.50%
controls:5.05%
cases:5.84%
controls:1.83%
—
—
—
—
—
—
cases:6.72%
controls:1.93%
cases:11.91%
controls:6.35%
32
129
224
2425
15
47
242
2517
—
—
—
17
49
236
2484
28
149
207
2198
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
9.9e-01
1.0e+00
—
—
—
2.2e+00
1.3e+00
cases:4.30%
controls:1.64%
cases:2.33%
controls:0.86%
—
—
—
—
—
—
cases:5.93%
controls:0.71%
cases:8.09%
controls:2.39%
11
42
245
2512
6
22
251
2542
—
—
—
15
18
238
2515
19
56
216
2291
oxycodone and naloxone; oral
N02AA55 [21604265]
1.2e+00
2.0e+00
—
—
—
1.9e+00
1.6e+00
cases:3.91%
controls:1.21%
cases:1.95%
controls:0.27%
—
—
—
—
—
—
cases:2.77%
controls:0.43%
cases:8.09%
controls:1.79%
10
31
246
2523
5
7
252
2557
—
—
—
7
11
246
2522
19
42
216
2305
zolpidem; oral
N05CF02 [21604655]
1.1e+00
1.1e+00
—
—
—
1.2e+00
6.7e-01
cases:9.38%
controls:3.33%
cases:5.06%
controls:1.76%
—
—
—
—
—
—
cases:5.93%
controls:1.78%
cases:7.23%
controls:3.83%
24
85
232
2469
13
45
244
2519
—
—
—
15
45
238
2488
17
90
218
2257
potassium chloride; oral
A12BA01 [21600877]
1.4e+00
2.0e+00
—
—
—
1.8e+00
9.4e-01
cases:3.91%
controls:0.98%
cases:3.11%
controls:0.43%
—
—
—
—
—
—
cases:2.37%
controls:0.39%
cases:3.40%
controls:1.36%
10
25
246
2529
8
11
249
2553
—
—
—
6
10
247
2523
8
32
227
2315
clindamycin; oral, parenteral
J01FF01 [21602985]
9.6e-01
1.5e+00
—
—
—
1.0e+00
9.8e-01
cases:10.16%
controls:4.15%
cases:5.06%
controls:1.21%
—
—
—
—
—
—
cases:3.16%
controls:1.14%
cases:9.36%
controls:3.75%
26
106
230
2448
13
31
244
2533
—
—
—
8
29
245
2504
22
88
213
2259
oxycodone; oral, parenteral
N02AA05 [21604260]
1.8e+00
1.5e+00
—
—
—
1.5e+00
1.6e+00
cases:3.91%
controls:0.67%
cases:2.33%
controls:0.51%
—
—
—
—
—
—
cases:2.77%
controls:0.63%
cases:6.38%
controls:1.36%
10
17
246
2537
6
13
251
2551
—
—
—
7
16
246
2517
15
32
220
2315
Specific gravity of Urine by Refractometry
5810-7 [3019150]
8.3e-01
1.5e+00
1.8e+00
—
—
1.2e+00
6.9e-01
cases:7.81%
controls:3.56%
cases:7.00%
controls:1.64%
cases:1.95%
controls:0.31%
—
—
—
—
cases:6.32%
controls:2.01%
cases:14.04%
controls:7.54%
20
91
236
2463
18
42
239
2522
5
8
252
2556
—
—
16
51
237
2482
33
177
202
2170
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
1.2e+00
—
—
—
—
2.0e+00
1.4e+00
cases:2.73%
controls:0.82%
—
—
—
—
—
—
—
—
cases:2.77%
controls:0.39%
cases:6.38%
controls:1.62%
7
21
249
2533
—
—
—
—
7
10
246
2523
15
38
220
2309
Puncture of maxillary antrum
TDM10 [2001301819]
3.4e+00
—
—
—
—
—
—
cases:5.47%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
14
5
242
2549
—
—
—
—
—
—
clonazepam; oral, parenteral
N03AE01 [21604415]
1.3e+00
1.6e+00
—
—
—
1.7e+00
1.4e+00
cases:3.91%
controls:1.06%
cases:3.50%
controls:0.74%
—
—
—
—
—
—
cases:3.95%
controls:0.71%
cases:3.83%
controls:0.98%
10
27
246
2527
9
19
248
2545
—
—
—
10
18
243
2515
9
23
226
2324
hydrocortisone and antiinfectives
S01CA03 [21603654]
1.4e+00
2.0e+00
—
—
—
—
1.1e+00
cases:4.69%
controls:1.25%
cases:2.72%
controls:0.39%
—
—
—
—
—
—
—
—
cases:3.83%
controls:1.28%
12
32
244
2522
7
10
250
2554
—
—
—
—
9
30
226
2317
dexamethasone and antiinfectives
S03CA01 [21605206]
1.3e+00
—
—
—
—
2.0e+00
1.1e+00
cases:5.08%
controls:1.41%
—
—
—
—
—
—
—
—
cases:3.95%
controls:0.55%
cases:5.11%
controls:1.83%
13
36
243
2518
—
—
—
—
10
14
243
2519
12
43
223
2304
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
1.2e+00
—
—
—
—
2.0e+00
1.3e+00
cases:2.73%
controls:0.86%
—
—
—
—
—
—
—
—
cases:2.77%
controls:0.39%
cases:5.96%
controls:1.66%
7
22
249
2532
—
—
—
—
7
10
246
2523
14
39
221
2308
Social worker
Z2446 [2001311559]
1.2e+00
9.3e-01
—
—
—
—
2.0e+00
cases:5.47%
controls:1.72%
cases:1.95%
controls:0.78%
—
—
—
—
—
—
—
—
cases:3.83%
controls:0.51%
14
44
242
2510
5
20
252
2544
—
—
—
—
9
12
226
2335
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
7.6e-01
6.3e-01
1.3e+00
—
1.5e+00
1.1e+00
1.3e+00
cases:10.55%
controls:5.25%
cases:6.61%
controls:3.63%
cases:2.33%
controls:0.62%
—
—
cases:2.33%
controls:0.55%
cases:11.07%
controls:3.83%
cases:26.81%
controls:8.78%
27
134
229
2420
17
93
240
2471
6
16
251
2548
—
6
14
251
2546
28
97
225
2436
63
206
172
2141
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
1.0e+00
1.3e+00
—
—
—
1.1e+00
9.0e-01
cases:9.77%
controls:3.72%
cases:5.06%
controls:1.48%
—
—
—
—
—
—
cases:4.35%
controls:1.54%
cases:9.36%
controls:4.05%
25
95
231
2459
13
38
244
2526
—
—
—
11
39
242
2494
22
95
213
2252
alprazolam; oral
N05BA12 [21604577]
1.6e+00
1.4e+00
—
—
—
1.6e+00
1.0e+00
cases:5.86%
controls:1.25%
cases:2.72%
controls:0.70%
—
—
—
—
—
—
cases:3.56%
controls:0.75%
cases:3.40%
controls:1.24%
15
32
241
2522
7
18
250
2546
—
—
—
9
19
244
2514
8
29
227
2318
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
7.7e-01
9.7e-01
—
—
2.0e+00
8.8e-01
1.2e+00
cases:7.03%
controls:3.37%
cases:5.84%
controls:2.30%
—
—
—
—
cases:2.72%
controls:0.39%
cases:6.32%
controls:2.72%
cases:18.72%
controls:6.48%
18
86
238
2468
15
59
242
2505
—
—
7
10
250
2550
16
69
237
2464
44
152
191
2195
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
9.4e-01
1.7e+00
—
—
—
1.3e+00
1.4e+00
cases:3.52%
controls:1.41%
cases:3.89%
controls:0.70%
—
—
—
—
—
—
cases:2.37%
controls:0.63%
cases:8.09%
controls:2.09%
9
36
247
2518
10
18
247
2546
—
—
—
6
16
247
2517
19
49
216
2298
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
4.7e-01
2.3e+00
—
—
—
9.3e-01
8.6e-01
cases:4.30%
controls:2.74%
cases:5.84%
controls:0.62%
—
—
—
—
—
—
cases:2.37%
controls:0.95%
cases:8.94%
controls:4.01%
11
70
245
2484
15
16
242
2548
—
—
—
6
24
247
2509
21
94
214
2253
CBC panel - Blood by Automated count
58410-2 [40761511]
2.1e-01
4.9e-01
1.3e+00
—
1.3e+00
6.0e-01
4.4e-01
cases:27.34%
controls:23.30%
cases:25.29%
controls:17.20%
cases:10.12%
controls:3.08%
—
—
cases:8.17%
controls:2.46%
cases:26.48%
controls:16.50%
cases:51.06%
controls:40.22%
70
595
186
1959
65
441
192
2123
26
79
231
2485
—
21
63
236
2497
67
418
186
2115
120
944
115
1403
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
1.3e+00
—
—
—
—
1.8e+00
—
cases:6.25%
controls:1.72%
—
—
—
—
—
—
—
—
cases:2.77%
controls:0.47%
—
—
16
44
240
2510
—
—
—
—
7
12
246
2521
—
Acute cystitis
N30.0 [45601724]
1.3e+00
2.0e+00
—
—
—
1.6e+00
1.1e+00
cases:3.13%
controls:0.90%
cases:2.33%
controls:0.31%
—
—
—
—
—
—
cases:2.77%
controls:0.55%
cases:5.96%
controls:2.13%
8
23
248
2531
6
8
251
2556
—
—
—
7
14
246
2519
14
50
221
2297
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
1.7e+00
—
—
—
—
—
1.4e+00
cases:3.13%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:1.11%
8
15
248
2539
—
—
—
—
—
10
26
225
2321
metronidazole; oral, rectal
P01AB01 [21604857]
8.3e-01
1.2e+00
—
—
—
1.1e+00
3.3e-01
cases:14.45%
controls:6.85%
cases:7.00%
controls:2.30%
—
—
—
—
—
—
cases:5.53%
controls:1.97%
cases:8.09%
controls:5.97%
37
175
219
2379
18
59
239
2505
—
—
—
14
50
239
2483
19
140
216
2207
Pain localized to upper abdomen
R10.1 [45568111]
8.7e-01
2.1e+00
—
—
—
1.5e+00
9.7e-01
cases:4.30%
controls:1.84%
cases:3.89%
controls:0.51%
—
—
—
—
—
—
cases:2.37%
controls:0.51%
cases:6.81%
controls:2.68%
11
47
245
2507
10
13
247
2551
—
—
—
6
13
247
2520
16
63
219
2284
CD3 cells [#/volume] in Blood
8122-4 [3011412]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.11%
controls:0.26%
—
—
—
—
—
—
12
6
223
2341
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
1.1e+00
1.4e+00
—
—
—
1.9e+00
5.5e-01
cases:7.03%
controls:2.39%
cases:1.95%
controls:0.47%
—
—
—
—
—
—
cases:3.56%
controls:0.55%
cases:5.96%
controls:3.54%
18
61
238
2493
5
12
252
2552
—
—
—
9
14
244
2519
14
83
221
2264
Headache
R51.80 [2000503603]
9.0e-01
2.0e+00
—
—
—
—
1.0e+00
cases:4.69%
controls:1.96%
cases:5.45%
controls:0.78%
—
—
—
—
—
—
—
—
cases:7.23%
controls:2.73%
12
50
244
2504
14
20
243
2544
—
—
—
—
17
64
218
2283
Acute bronchitis, unspecified
J20.9 [45562445]
1.6e+00
—
—
—
—
—
1.4e+00
cases:9.38%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
cases:8.94%
controls:2.30%
24
54
232
2500
—
—
—
—
—
21
54
214
2293
esomeprazole; oral, parenteral
A02BC05 [21600100]
9.1e-01
1.0e+00
1.3e+00
—
8.8e-01
1.1e+00
6.3e-01
cases:17.97%
controls:8.10%
cases:9.73%
controls:3.74%
cases:1.95%
controls:0.55%
—
—
cases:2.33%
controls:0.98%
cases:9.49%
controls:3.51%
cases:13.62%
controls:7.75%
46
207
210
2347
25
96
232
2468
5
14
252
2550
—
6
25
251
2535
24
89
229
2444
32
182
203
2165
Urinary tract infection, site not specified
N39.0 [45548665]
1.7e+00
1.6e+00
—
—
—
2.0e+00
1.3e+00
cases:4.30%
controls:0.82%
cases:1.95%
controls:0.39%
—
—
—
—
—
—
cases:1.98%
controls:0.28%
cases:5.53%
controls:1.58%
11
21
245
2533
5
10
252
2554
—
—
—
5
7
248
2526
13
37
222
2310
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
8.2e-01
7.1e-01
1.4e-01
—
8.1e-01
8.1e-01
6.3e-01
cases:16.02%
controls:7.71%
cases:15.18%
controls:8.07%
cases:2.72%
controls:2.38%
—
—
cases:5.06%
controls:2.30%
cases:17.00%
controls:8.37%
cases:17.87%
controls:10.35%
41
197
215
2357
39
207
218
2357
7
61
250
2503
—
13
59
244
2501
43
212
210
2321
42
243
193
2104
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
—
2.3e+00
—
—
—
—
3.0e+00
—
—
cases:1.95%
controls:0.20%
—
—
—
—
—
—
—
—
cases:5.53%
controls:0.30%
—
5
5
252
2559
—
—
—
—
13
7
222
2340
Dentistry
C5 [903277]
7.3e-01
1.1e+00
—
—
—
1.7e+00
1.3e+00
cases:3.91%
controls:1.92%
cases:2.72%
controls:0.94%
—
—
—
—
—
—
cases:3.95%
controls:0.75%
cases:6.81%
controls:2.05%
10
49
246
2505
7
24
250
2540
—
—
—
10
19
243
2514
16
48
219
2299
General Practice
1 [38004446]
5.6e-01
1.1e+00
—
—
—
9.9e-01
8.2e-01
cases:16.02%
controls:9.83%
cases:10.89%
controls:3.82%
—
—
—
—
—
—
cases:9.49%
controls:3.75%
cases:21.28%
controls:10.61%
41
251
215
2303
28
98
229
2466
—
—
—
24
95
229
2438
50
249
185
2098
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
3.3e-01
7.1e-01
1.4e+00
—
1.2e+00
8.3e-01
4.3e-01
cases:17.97%
controls:13.55%
cases:17.12%
controls:9.20%
cases:4.67%
controls:1.21%
—
—
cases:3.50%
controls:1.09%
cases:19.37%
controls:9.51%
cases:36.60%
controls:27.23%
46
346
210
2208
44
236
213
2328
12
31
245
2533
—
9
28
248
2532
49
241
204
2292
86
639
149
1708
CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood
14135-8 [3001405]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.83%
controls:0.21%
—
—
—
—
—
—
9
5
226
2342
CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood
9728-7 [3025271]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.83%
controls:0.21%
—
—
—
—
—
—
9
5
226
2342
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
313 [2001600274]
2.9e+00
—
—
—
—
—
—
cases:3.52%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
—
9
5
247
2549
—
—
—
—
—
—
Left side
ZXA05 [2001311347]
2.6e-01
—
—
—
—
1.9e+00
1.0e+00
cases:4.69%
controls:3.64%
—
—
—
—
—
—
—
—
cases:3.56%
controls:0.55%
cases:6.38%
controls:2.39%
12
93
244
2461
—
—
—
—
9
14
244
2519
15
56
220
2291
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.8e-01
4.3e-01
1.1e+00
—
1.2e+00
5.1e-01
5.7e-01
cases:16.41%
controls:14.13%
cases:18.68%
controls:12.99%
cases:7.78%
controls:2.65%
—
—
cases:7.78%
controls:2.46%
cases:20.16%
controls:13.15%
cases:40.85%
controls:27.99%
42
361
214
2193
48
333
209
2231
20
68
237
2496
—
20
63
237
2497
51
333
202
2200
96
657
139
1690
codeine and paracetamol
N02AJ06 [1123647]
5.2e-01
9.9e-01
6.6e-01
—
1.2e+00
1.1e+00
7.1e-01
cases:19.53%
controls:12.61%
cases:12.84%
controls:5.19%
cases:1.95%
controls:1.01%
—
—
cases:3.11%
controls:0.94%
cases:13.83%
controls:4.97%
cases:26.81%
controls:15.21%
50
322
206
2232
33
133
224
2431
5
26
252
2538
—
8
24
249
2536
35
126
218
2407
63
357
172
1990
Rheumatism, unspecified
M79.0 [45567658]
2.8e+00
—
—
—
—
—
—
cases:4.30%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
11
7
245
2547
—
—
—
—
—
—
Dermatitis, unspecified
L30.9 [45572271]
7.5e-01
1.7e+00
—
—
—
—
1.1e+00
cases:3.52%
controls:1.68%
cases:3.11%
controls:0.59%
—
—
—
—
—
—
—
—
cases:10.21%
controls:3.75%
9
43
247
2511
8
15
249
2549
—
—
—
—
24
88
211
2259
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.0e-01
1.1e+00
1.4e+00
—
1.4e+00
8.4e-01
8.0e-01
cases:17.19%
controls:11.20%
cases:14.40%
controls:5.23%
cases:3.50%
controls:0.90%
—
—
cases:3.11%
controls:0.78%
cases:11.86%
controls:5.49%
cases:31.06%
controls:16.87%
44
286
212
2268
37
134
220
2430
9
23
248
2541
—
8
20
249
2540
30
139
223
2394
73
396
162
1951
lercanidipine; oral
C08CA13 [21601759]
9.6e-01
1.2e+00
1.4e+00
—
1.8e+00
1.4e+00
1.3e+00
cases:3.91%
controls:1.53%
cases:4.28%
controls:1.33%
cases:1.95%
controls:0.47%
—
—
cases:1.95%
controls:0.31%
cases:5.14%
controls:1.30%
cases:7.66%
controls:2.13%
10
39
246
2515
11
34
246
2530
5
12
252
2552
—
5
8
252
2552
13
33
240
2500
18
50
217
2297
adalimumab; parenteral
L04AB04 [21603911]
2.7e+00
—
—
—
—
—
—
cases:3.52%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
9
6
247
2548
—
—
—
—
—
—
Hemolysis interference index of Serum or Plasma
46424-8 [3052851]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:0.30%
—
—
—
—
—
—
10
7
225
2340

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
118
96
21.42
128.90
2.5
1.5
0.19
0.23
g/l
3.49
100
96
61
26
30.21
87.51
2.8
1.3
—
—
—
0
0
58
25
29.45
82.71
2.7
1.4
0.31
0.39
g/l
0.61
50
20
58
25
29.45
82.71
2.7
1.4
2.68
2.89
g/l
0.17
50
19
58
25
29.45
82.71
2.7
1.4
5.12
6.92
g/l
1.92
50
20
65
50
16.92
70.84
2.6
2.4
0.69
0.75
g/l
0.07
55
45
171
814
4.12
27.60
13.9
7.0
—
—
—
0
0
218
1273
5.09
25.45
16.6
7.0
0.57
0.54
e9/l
1.12
212
1084
218
1274
5.08
25.40
16.7
7.0
0.04
0.04
e9/l
0.73
212
1079
103
369
3.94
24.72
2.1
1.4
512.73
551.81
titre
0.09
22
83
218
1295
4.92
24.29
16.8
7.0
2.13
2.05
e9/l
0.37
212
1137
29
8
40.47
23.53
3.1
1.3
740.41
1385.25
u/ml
—
29
8
218
1315
4.78
23.27
17.1
7.3
0.19
0.19
e9/l
0.22
213
1144
42
81
5.98
21.59
1.4
1.2
—
—
—
0
0
50
115
5.13
21.18
2.2
1.7
7.10
4.68
iu/ml
0.27
16
22
139
670
3.27
20.07
3.1
1.5
1.79
2.08
g/l
1.57
118
393
27
35
8.48
19.92
4.5
2.8
4.15
4.86
e9/l
0.66
27
35
197
1179
3.64
19.57
15.8
6.9
55.19
55.33
%
0.06
197
1140
219
1406
4.27
19.46
18.6
10.2
3.97
3.85
e9/l
0.43
213
1211
192
1145
3.48
18.88
20.5
10.9
0.00
0.00
e9/l
0.70
166
912
124
583
3.13
18.28
10.4
5.0
—
—
—
0
0
112
510
3.08
17.27
7.4
3.8
—
—
—
0
0
164
984
2.76
14.23
17.2
8.6
1.20
1.22
mmol/l
1.78
157
919
58
201
3.42
13.83
5.9
5.9
0.86
0.79
%
0.08
21
64
30
64
5.16
13.67
4.2
2.4
59.78
60.42
%
0.10
30
64
56
193
3.41
13.45
5.9
5.6
0.39
0.65
%
0.57
18
55
67
259
3.13
13.32
3.3
1.6
—
—
—
0
0
172
1088
2.67
12.92
12.8
8.4
1.21
1.22
mmol/l
0.68
153
964
41
119
3.89
12.68
4.7
2.3
—
—
—
0
0
54
190
3.32
12.50
6.2
6.1
0.00
0.10
%
1.24
17
52
55
196
3.28
12.47
6.2
6.3
0.00
0.08
%
0.49
17
49
117
625
2.57
12.41
7.4
4.3
7.41
7.39
ph
1.82
77
406
168
1067
2.58
12.25
4.0
2.8
76.43
74.80
nmol/l
0.34
158
979
112
589
2.57
12.24
5.3
2.5
2.79
2.78
mg/l
0.03
104
514
74
317
2.85
12.15
3.1
2.0
—
—
—
0
0
90
430
2.66
11.93
4.5
2.7
496.40
530.06
mosm/kgh2o
0.84
85
374
152
929
2.50
11.93
9.4
5.3
36.80
36.85
g/l
0.04
146
882
23
25
9.97
11.76
5.3
1.4
—
—
—
0
0
130
747
2.46
11.58
10.7
6.8
—
—
—
0
0
188
1291
2.58
11.13
11.9
5.5
6.38
6.44
mmol/l
0.17
182
1209
227
1720
3.28
10.97
16.8
7.5
77.63
82.53
u/l
1.06
221
1626
176
1187
2.45
10.60
8.5
6.4
11.40
11.92
umol/l
0.14
167
1126
115
646
2.38
10.54
5.5
3.3
0.67
0.32
e6/l
0.28
95
446
32
90
3.91
10.29
1.2
1.2
—
—
—
0
0
113
646
2.31
9.78
3.6
2.0
117.07
156.01
u/l
1.21
108
622
125
751
2.26
9.55
5.8
3.4
88.84
53.80
e6/l
0.21
105
550
27
72
4.06
9.32
20.6
6.3
—
—
—
0
0
19
40
5.04
8.73
3.3
2.6
—
—
—
0
0
138
890
2.15
8.56
7.0
4.2
121.88
67.35
e6/l
0.23
110
578
96
538
2.23
8.48
3.3
2.2
0.99
1.23
mg/l
0.44
84
416
20
32
6.67
8.19
1.8
1.7
—
—
—
0
0
113
684
2.14
8.16
3.7
2.5
51.98
65.27
u/l
1.21
108
638
19
44
4.58
7.82
1.2
1.3
3.00
3.52
u/ml
—
9
25
21
54
4.14
7.59
2.8
2.6
4.79
1.49
index
0.52
14
31
46
199
2.59
7.16
5.4
6.8
5.15
5.08
kpa
0.22
46
191
74
396
2.21
7.16
5.1
2.7
121.63
80.15
ug/g
0.55
64
318
55
260
2.41
7.10
1.6
1.4
—
—
—
0
0
17
39
4.59
7.07
3.4
2.6
9.56
9.21
kpa
0.30
17
39
17
39
4.59
7.07
3.5
2.6
4.79
4.93
kpa
0.34
17
39
99
597
2.05
7.00
1.8
1.6
22.10
20.71
nmol/l
0.40
87
517
50
228
2.47
6.97
20.4
11.2
—
—
—
0
0
57
279
2.33
6.79
16.5
7.4
7.38
7.38
ph
0.19
31
167
33
126
2.85
6.52
23.8
7.0
0.69
0.61
%
0.86
33
126
42
183
2.54
6.43
3.1
3.6
82.02
72.39
e9/l
0.81
28
132
33
127
2.83
6.42
23.8
7.0
1.46
1.26
%
0.42
33
127
144
1012
1.93
6.39
5.9
3.3
6.12
6.21
ph
0.38
75
543
129
876
1.92
6.33
15.1
9.5
1.14
1.14
inr
0.04
108
709
70
384
2.12
6.28
1.9
1.6
60317947.98
55090268.72
pmol/l
0.03
63
334
57
288
2.25
6.27
1.7
1.7
1509.68
1167.73
nmol/l
1.57
45
225
17
32
5.60
6.27
1.2
1.3
—
—
—
0
0
114
746
1.93
6.23
5.7
3.3
15.36
29.81
ng/l
1.92
77
429
54
269
2.27
6.14
4.3
4.3
4.45
6.82
umol/l
1.07
44
239
47
221
2.37
6.10
13.9
13.9
24.37
24.59
mmol/l
0.22
47
221
45
209
2.39
6.00
1.7
1.3
47.33
161.68
u/ml
3.51
13
88
58
301
2.19
5.97
3.1
1.4
—
—
—
0
0
53
267
2.23
5.86
17.5
7.6
1.62
1.44
mmol/l
0.14
48
222
45
212
2.35
5.81
10.2
9.0
1.62
0.83
mmol/l
0.72
39
171
68
381
2.06
5.72
4.0
3.5
2.17
2.96
e6/l
0.47
41
185
19
56
3.58
5.70
3.6
2.9
7.42
7.42
ph
0.15
19
56
52
264
2.21
5.63
2.3
1.5
—
—
—
0
0
164
1237
1.86
5.52
5.0
3.3
89.40
84.16
ug/l
0.23
159
1173
15
29
5.42
5.48
1.5
1.6
—
—
—
0
0
15
29
5.42
5.48
1.5
1.6
—
—
—
0
0
15
29
5.42
5.48
1.5
1.6
—
—
—
0
0
15
29
5.42
5.48
1.5
1.6
—
—
—
0
0
45
218
2.28
5.44
10.8
8.9
7.42
7.42
ph
0.20
20
122
16
34
4.94
5.40
2.1
1.8
1.62
1.45
mmol/l
0.30
16
34
53
276
2.15
5.38
22.8
8.9
103.40
104.52
mmol/l
0.66
53
276
9
9
10.30
5.06
1.6
1.6
11.30
10.56
umol/l
—
9
9
33
145
2.46
4.95
1.3
1.2
—
—
—
0
0
112
775
1.77
4.82
3.5
3.1
2.33
2.36
mmol/l
2.45
104
723
39
191
2.22
4.58
13.3
10.7
9.70
7.04
mmol/l
1.09
39
184
22
82
2.84
4.54
1.2
1.1
3.87
5.01
u/ml
0.16
15
52
105
723
1.75
4.53
2.7
2.5
—
—
—
0
0
97
653
1.77
4.53
4.4
2.7
—
—
—
0
0
24
94
2.71
4.53
1.6
1.1
—
—
—
0
0
83
536
1.80
4.45
2.2
2.1
—
—
—
0
0
22
84
2.77
4.35
1.1
1.1
1.98
0.78
u/ml
0.34
15
55
124
911
1.68
4.13
2.5
2.0
98.55
96.53
pmol/l
0.20
74
459
15
47
3.32
4.12
7.9
4.6
6.12
1.95
ratio
—
10
21
24
99
2.57
4.10
10.5
4.6
—
—
—
0
0
8
10
8.21
4.09
2.1
3.4
0.50
0.60
index
—
8
10
22
87
2.67
4.08
1.5
1.6
34.33
9.84
u/ml
—
6
20
36
180
2.16
4.02
7.3
3.4
—
—
—
0
0
79
517
1.75
3.99
1.7
1.3
19.22
24.75
iu/ml
0.40
29
155
10
19
5.43
3.86
1.1
1.3
119.50
101.42
pmol/l
—
10
19
63
390
1.81
3.83
3.7
3.5
33.94
458.94
ng/l
3.42
33
263
160
1275
1.65
3.75
7.0
3.6
0.00
0.00
estimate
-0.00
42
256
19
73
2.73
3.73
1.8
1.4
364.11
305.69
ug/g
—
9
38
20
79
2.66
3.73
1.1
1.1
0.63
0.71
u/ml
0.05
14
45
10
20
5.15
3.72
1.1
1.2
0.07
0.12
u/ml
—
5
7
159
1267
1.64
3.71
7.0
3.5
0.00
0.00
estimate
0.50
42
252
14
40
3.64
3.67
4.1
2.8
5.32
8.42
pmol/l
0.73
14
40
18
68
2.77
3.64
1.2
1.1
1.25
6.19
u/ml
—
10
39
12
30
4.14
3.64
2.3
2.1
—
—
—
0
0
10
21
4.91
3.59
1.0
1.2
—
—
—
0
0
7
9
7.95
3.58
2.1
1.8
140.14
139.56
nmol/l
—
7
9
160
1284
1.62
3.57
7.1
3.6
0.00
0.01
estimate
0.50
42
240
72
473
1.72
3.55
1.5
1.3
5.97
11.26
u/ml
0.70
27
191
6
6
10.19
3.51
1.3
2.8
197.17
168.83
ug/g
—
6
6
22
95
2.44
3.44
1.2
1.2
0.35
4.19
u/ml
1.93
16
59
12
32
3.88
3.43
1.5
1.2
—
—
nmol/l
—
0
0
9
18
5.14
3.40
2.9
1.7
—
—
—
0
0
10
23
4.48
3.34
1.2
1.3
—
—
—
0
0
94
672
1.62
3.32
8.0
3.5
0.00
0.00
estimate
0.50
42
243
50
302
1.81
3.27
1.4
1.2
—
—
—
0
0
123
941
1.58
3.26
6.8
3.3
0.00
0.02
estimate
0.88
35
217
17
67
2.64
3.19
1.2
1.2
—
—
—
0
0
17
67
2.64
3.19
1.2
1.2
—
—
—
0
0
13
44
3.06
3.18
2.5
1.7
24.07
18.77
ng/l
0.54
13
44
135
1060
1.56
3.16
3.2
2.8
—
—
estimate
—
0
0
10
25
4.12
3.12
1.3
1.2
—
—
—
0
0
35
191
1.96
3.11
21.4
8.9
24.37
23.84
mmol/l
0.59
35
191
16
62
2.68
3.10
1.4
1.8
113.53
148.06
au/ml
—
6
22
13
41
3.28
3.10
1.3
1.2
—
—
—
0
0
101
745
1.58
3.09
1.6
1.5
0.46
1.54
u/ml
2.51
32
205
25
122
2.16
2.98
1.8
1.6
—
—
—
0
0
12
37
3.35
2.97
1.0
1.1
—
—
—
0
0
96
706
1.57
2.96
5.1
3.0
0.00
0.01
estimate
0.74
39
213
16
64
2.60
2.93
1.1
1.1
3.77
7.70
u/ml
—
8
34
63
419
1.66
2.92
1.9
2.3
2.44
2.44
mmol/l
0.17
55
377
6
9
6.79
2.88
2.5
2.9
—
—
—
0
0
61
404
1.66
2.87
1.8
1.7
—
—
—
0
0
7
14
5.10
2.74
1.0
1.4
—
—
—
0
0
10
29
3.54
2.72
1.2
1.1
0.51
0.37
u/ml
—
5
16
6
10
6.11
2.71
3.8
1.3
95.50
64.40
nmol/24h
—
6
10
8
19
4.31
2.70
1.8
1.4
—
—
—
0
0
13
49
2.74
2.66
1.3
1.1
—
—
—
0
0
6
11
5.55
2.55
2.3
2.0
4.27
4.91
mg/l
—
6
11
21
102
2.15
2.55
1.3
1.5
9.93
10.74
u/l
0.10
15
70
23
116
2.08
2.54
19.3
6.6
25.59
24.57
mmol/l
0.57
23
109
17
77
2.29
2.43
1.8
1.3
—
—
—
0
0
212
1901
1.58
2.31
6.0
4.6
14.46
14.54
pmol/l
0.17
205
1771
10
34
3.02
2.30
1.7
1.2
—
—
—
0
0
8
23
3.55
2.29
1.0
1.0
—
—
—
0
0
5
9
5.64
2.22
4.2
3.2
0.63
0.61
mmol/l
—
5
9
15
67
2.31
2.22
1.9
1.7
174.90
239.00
u/ml
—
10
39
13
56
2.39
2.08
1.2
1.1
0.14
0.07
u/ml
—
7
24
9
32
2.87
2.02
1.8
1.2
—
—
—
0
0
31
189
1.73
1.98
1.5
1.4
—
—
—
0
0
10
39
2.62
1.96
1.0
1.1
—
—
—
0
0
248
2340
1.99
1.95
40.8
13.2
21.35
21.49
mg/l
0.03
221
1824
5
11
4.61
1.95
1.2
1.0
—
—
—
0
0
5
11
4.61
1.95
1.2
1.0
—
—
—
0
0
6
16
3.81
1.94
5.2
4.4
—
—
—
0
0
6
16
3.81
1.94
1.0
1.1
—
—
—
0
0
9
34
2.70
1.88
1.7
1.3
—
—
—
0
0
5
12
4.22
1.83
1.4
1.2
—
—
—
0
0
96
765
1.40
1.83
5.2
3.3
7.78
8.09
mmol/l
0.25
89
659
30
186
1.69
1.82
1.3
1.2
—
15.00
—
0
5
26
156
1.74
1.77
7.6
7.7
—
—
—
0
0
45
312
1.53
1.75
1.2
1.2
—
—
—
0
0
22
126
1.81
1.74
1.8
1.3
0.16
0.32
mg/l
1.40
14
56
5
13
3.90
1.72
1.4
2.1
—
—
—
0
0
5
13
3.90
1.72
1.0
1.2
—
—
—
0
0
113
938
1.36
1.64
2.3
2.0
—
—
—
0
0
5
15
3.38
1.53
1.4
1.4
—
—
—
0
0
16
87
1.89
1.49
1.3
1.1
—
—
—
0
0
5
17
2.98
1.36
1.6
1.5
—
—
—
0
0
5
17
2.98
1.36
1.0
1.1
—
—
—
0
0
70
555
1.36
1.33
7.4
3.4
1.02
1.02
kg/l
0.33
41
357
178
1616
1.31
1.25
6.1
3.6
44.44
39.94
u/l
0.47
171
1550
80
654
1.32
1.24
6.1
3.9
6.67
8.48
mg/mmol
0.23
49
397
18
109
1.70
1.22
2.0
1.8
—
—
—
0
0
5
19
2.66
1.22
1.0
1.2
—
—
—
0
0
231
2188
1.45
1.18
6.9
5.5
1.73
1.87
mu/l
1.17
225
2062
5
20
2.53
1.15
1.2
1.1
—
—
—
0
0
195
2082
0.76
1.15
4.3
4.0
1.39
1.26
mmol/l
1.98
184
1956
56
443
1.34
1.08
2.0
1.8
—
—
—
0
0
9
46
1.99
1.04
1.0
1.1
—
—
—
0
0
78
651
1.28
1.02
5.1
3.3
27.40
50.36
mg/l
1.12
48
416
17
107
1.63
1.02
13.8
11.2
15.41
15.88
%
0.39
17
102
42
321
1.37
1.01
2.1
1.7
—
—
—
0
0
5
23
2.20
0.98
1.0
1.1
—
—
—
0
0
11
63
1.78
0.91
53.3
10.7
61.65
65.23
%
0.18
11
63
23
163
1.45
0.85
1.3
1.2
—
—
—
0
0
251
2439
1.59
0.85
39.8
15.9
72.67
69.57
umol/l
0.62
251
2411
203
2133
0.79
0.83
5.1
4.5
5.79
5.77
mmol/l
0.10
196
2001
23
165
1.43
0.81
4.7
4.4
7.35
7.36
ph
0.07
17
116
10
58
1.75
0.81
58.6
10.8
68.30
63.38
%
—
10
58
0
25
0.00
0.79
0.0
1.4
—
—
—
0
0
0
25
0.00
0.79
0.0
11.6
—
0.69
—
0
25
0
27
0.00
0.78
0.0
16.6
—
878.30
—
0
27
5
26
1.94
0.71
1.6
2.5
4.00
3.97
mmol/l
—
5
26
5
26
1.94
0.71
1.6
2.5
1.20
1.18
mmol/l
—
5
26
5
26
1.94
0.71
1.6
2.5
103.40
105.85
mmol/l
—
5
26
5
26
1.94
0.71
1.8
2.2
33.20
32.65
pg
—
5
26
5
26
1.94
0.71
2.6
2.6
1.12
3.41
nmol/l
—
5
26
13
85
1.56
0.70
7.2
5.4
244.20
305.11
mg/l
—
5
44
13
191
0.66
0.69
3.1
2.1
6.06
6.20
ph
—
8
127
213
2213
0.81
0.66
5.7
5.4
2.79
2.80
mmol/l
0.06
204
2092
26
199
1.34
0.65
1.7
1.5
—
—
—
0
0
19
138
1.41
0.64
3.6
2.3
1005.50
5815.40
u/l
—
6
51
24
183
1.34
0.62
1.2
1.3
—
26.04
—
0
11
8
51
1.59
0.61
3.6
4.2
—
—
—
0
0
16
114
1.43
0.60
3.9
2.0
0.00
0.02
estimate
—
8
41
211
2187
0.82
0.57
4.9
4.7
1.47
1.50
mmol/l
0.39
202
2063
5
90
0.55
0.56
1.2
1.1
1.78
1.59
g/l
—
5
90
6
38
1.59
0.54
1.0
1.3
—
—
—
0
0
11
74
1.51
0.54
1.2
1.7
—
—
—
0
0
7
49
1.44
0.46
1.6
1.9
—
—
—
0
0
246
2412
1.29
0.43
24.9
11.5
—
—
—
0
0
6
94
0.63
0.43
1.8
1.2
0.80
0.87
g/l
—
6
94
25
204
1.25
0.42
3.3
3.9
17.51
8.16
ug/l
0.27
18
158
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
5.2
—
2.24
—
0
17
18
222
0.80
0.36
1.3
1.7
3.14
3.44
mmol/l
—
10
164
214
2195
0.87
0.36
4.9
4.8
4.72
4.74
mmol/l
0.11
204
2080
10
73
1.38
0.35
1.7
1.8
1.11
5.68
iu/l
—
5
31
209
2036
1.13
0.30
7.0
5.7
39.39
38.34
mmol/mol
0.81
203
1941
77
713
1.11
0.30
1.5
1.6
—
—
—
0
0
32
282
1.15
0.27
1.0
1.2
—
—
—
0
0
5
73
0.68
0.26
1.2
1.5
—
—
—
0
0
34
302
1.14
0.26
1.7
1.9
—
—
—
0
0
5
75
0.66
0.26
1.2
1.6
—
—
—
0
0
13
157
0.82
0.23
2.1
1.7
—
—
—
0
0
10
79
1.28
0.22
1.3
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
217.98
—
0
11
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
93
972
0.93
0.18
2.5
3.0
—
—
—
0
0
7
58
1.21
0.18
1.3
2.0
—
—
—
0
0
7
59
1.19
0.18
1.7
2.7
—
—
—
0
0
12
101
1.20
0.17
2.2
2.2
—
—
—
0
0
17
149
1.15
0.16
2.2
1.5
—
—
—
0
0
9
81
1.11
0.15
1.1
1.3
—
—
—
0
0
17
150
1.14
0.15
2.2
1.5
—
—
—
0
0
17
150
1.14
0.15
2.2
1.5
—
—
—
0
0
16
143
1.13
0.12
2.3
1.5
—
—
—
0
0
10
114
0.87
0.09
2.6
3.0
1.02
1.02
ratio
—
10
106
6
55
1.09
0.09
2.0
2.9
2.08
4.99
u/ml
—
6
55
256
2562
0.97
0.07
49.7
20.9
133.82
134.74
g/l
0.56
256
2543
103
1010
1.03
0.06
1.9
1.9
1.38
1.36
mmol/l
0.07
90
881
32
335
0.95
0.06
4.1
5.0
2.12
1.66
ug/l
0.24
25
300
16
148
1.09
0.06
2.3
1.5
—
—
—
0
0
14
150
0.93
0.04
1.1
1.1
—
—
—
0
0
15
143
1.05
0.01
1.2
1.1
—
—
—
0
0
21
211
0.99
0.00
3.3
1.9
0.00
0.07
estimate
—
9
45
208
2081
1.00
0.00
42.8
17.2
331.63
332.46
g/l
0.61
208
2076
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
101.80
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
10.97
—
0
6
8
85
0.94
-0.00
2.5
1.7
—
—
—
0
0
256
2560
1.00
-0.00
48.8
20.6
29.86
30.06
pg
0.96
256
2543
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.42
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
256
2560
1.00
-0.00
50.4
21.3
40.33
40.33
%
0.00
256
2542
256
2559
1.01
-0.00
48.9
20.7
89.95
90.16
fl
0.28
256
2542
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
4.66
—
0
6

Mortality – FinRegistry

↥

Association

Association between endpoint D3_COMPLEMENTDEF and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have D3_COMPLEMENTDEF.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: D3_COMPLEMENTDEF – Defects in the complement system

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data